{"id":"tucatinib","rwe":[{"pmid":"41899598","year":"2026","title":"Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"41899536","year":"2026","title":"Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"41899309","year":"2026","title":"Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41851506","year":"2026","title":"Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2(+) breast cancer: TBCRC049 phase 2 study results.","finding":"","journal":"Nature cancer","studyType":"Clinical Study"},{"pmid":"41824101","year":"2026","title":"Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.","finding":"","journal":"Breast cancer research and treatment","studyType":"Clinical Study"}],"_fda":{"id":"892c322b-be43-4180-89f7-4e3619a8b58f","set_id":"f27eb1b9-b7fc-424e-988f-84dd7bb195a3","openfda":{"nui":["N0000175605","N0000020001","N0000190114","N0000185503","N0000187062"],"unii":["234248D0HH"],"route":["ORAL"],"rxcui":["2361290","2361296","2361298","2361300"],"spl_id":["892c322b-be43-4180-89f7-4e3619a8b58f"],"brand_name":["TUKYSA"],"spl_set_id":["f27eb1b9-b7fc-424e-988f-84dd7bb195a3"],"package_ndc":["51144-001-60","51144-002-60","51144-002-12"],"product_ndc":["51144-001","51144-002"],"generic_name":["TUCATINIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["TUCATINIB"],"pharm_class_epc":["Kinase Inhibitor [EPC]"],"pharm_class_moa":["Tyrosine Kinase Inhibitors [MoA]","Cytochrome P450 3A Inhibitors [MoA]","P-Glycoprotein Inhibitors [MoA]","Cytochrome P450 2C8 Inhibitors [MoA]"],"manufacturer_name":["SEAGEN INC."],"application_number":["NDA213411"],"is_original_packager":[true]},"version":"9","pregnancy":["8.1 Pregnancy Risk Summary TUKYSA is used in combination with trastuzumab and capecitabine. Refer to the Full Prescribing Information of trastuzumab and capecitabine for pregnancy information. Based on findings in animals and its mechanism of action, TUKYSA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available human data on TUKYSA use in pregnant women to inform a drug-associated risk. In animal reproduction studies, administration of tucatinib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal mortality, reduced fetal weight and fetal abnormalities at maternal exposures ≥ 1.3 times the human exposure (AUC) at the recommended dose (see Data ) . Advise pregnant women and females of reproductive potential of the potential risk to the fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Data Animal Data In pilot embryo-fetal development studies, pregnant rats and rabbits received oral doses of tucatinib up to 150 mg/kg/day during the period of organogenesis. In rats, oral administration of tucatinib resulted in maternal toxicity (body weight loss, reduced body weight gain, low food consumption) at doses ≥ 90 mg/kg/day. Fetal effects included reduced number of live fetuses, decreased fetal weight, and fetal abnormalities (increase in skeletal variations, incomplete ossification) at ≥ 90 mg/kg/day (approximately 3.5 times the human exposure at the recommended dose based on AUC). In rabbits, oral administration of tucatinib resulted in increased resorptions, decreased percentages of live fetuses, and skeletal, visceral, and external malformations in fetuses at doses ≥ 90 mg/kg/day (1.3 times the human exposure at the recommended dose based on AUC). Fetal abnormalities included domed head, brain dilation, incomplete ossification of frontal and parietal bones, and a hole in the parietal bone."],"description":["11 DESCRIPTION Tucatinib is a kinase inhibitor. The chemical name is (N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. The molecular formula is C 26 H 24 N 8 O 2 and the molecular weight is 480.52 g/mol. The chemical structure is as follows: TUKYSA (tucatinib) is supplied as 50 mg and 150 mg film-coated tablets for oral use and contain the following inactive ingredients: Tablet core: copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose. Coating: yellow film coat: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, talc, and yellow iron oxide non-irradiated. Each TUKYSA 50 mg tablet contains 10.10 mg (0.258 mEq) potassium and 9.21 mg (0.401 mEq) sodium. Each TUKYSA 150 mg tablet contains 30.29 mg (0.775 mEq) potassium and 27.64 mg (1.202 mEq) sodium. structural formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied TUKYSA 50 mg tablets are supplied as yellow, film-coated, round tablets containing 50 mg of tucatinib. Each tablet is debossed with “TUC” on one side and “50” on the other side, and is packaged as follows: 50 mg tablets: 60 count in 75 cc bottle: NDC 51144-001-60 TUKYSA 150 mg tablets are supplied as yellow, film-coated, oval-shaped tablets containing 150 mg of tucatinib. Each tablet is debossed with “TUC” on one side and “150” on the other side, and is packaged as follows: 150 mg tablets: 60 count in 75 cc bottle: NDC 51144-002-60 150 mg tablets: 120 count in 150 cc bottle: NDC 51144-002-12 Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Dispense to patient in original container only. Store in original container to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant. Once opened, use within 3 months. Discard any unused tablets 3 months after opening the bottle."],"geriatric_use":["8.5 Geriatric Use In HER2CLIMB, 82 patients who received TUKYSA were ≥ 65 years, of whom 8 patients were ≥ 75 years. The incidence of serious adverse reactions in those receiving TUKYSA was 34% in patients ≥ 65 years compared to 24% in patients <65 years. The most frequent serious adverse reactions in patients ≥65 years who received TUKYSA were diarrhea (9%), vomiting (6%), and nausea (5%). There were no observed overall differences in the effectiveness of TUKYSA in patients ≥ 65 years compared to younger patients. There were too few patients ≥75 years to assess differences in effectiveness or safety. In MOUNTAINEER, 12 patients were ≥65 years of age. There were too few patients ≥65 years to assess differences in effectiveness or safety."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of TUKYSA in pediatric patients have not been established."],"effective_time":"20241104","clinical_studies":["14 CLINICAL STUDIES 14.1 HER2-Positive Metastatic Breast Cancer The efficacy of TUKYSA in combination with trastuzumab and capecitabine was evaluated in 612 patients in HER2CLIMB (NCT02614794), a randomized (2:1), double-blind, placebo-controlled trial. Patients were required to have HER2-positive, unresectable locally advanced or metastatic breast cancer, with or without brain metastases, and prior treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) separately or in combination, in the neoadjuvant, adjuvant or metastatic setting. HER2 positivity was based on archival or fresh tissue tested with an FDA-approved test at a central laboratory prior to enrollment with HER2 positivity defined as HER2 IHC 3+ or ISH positive. Patients with brain metastases, including those with progressing or untreated lesions, were eligible provided they were neurologically stable and did not require immediate radiation or surgery. The trial excluded patients with leptomeningeal disease. Randomization was stratified by the presence or history of brain metastases (yes vs. no), Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1), and region (U.S., Canada, or rest of world). Patients received TUKYSA 300 mg or placebo orally twice daily with a trastuzumab or a non-US approved trastuzumab product loading dose of 8 mg/kg on Day 1 of Cycle 1 if needed and then a maintenance dose of 6 mg/kg on Day 1 of every 21-day cycle thereafter and capecitabine 1000 mg/m 2 orally twice daily on Days 1 through 14 of every 21-day cycle. An alternate trastuzumab dosing regimen was 600 mg administered subcutaneously on Day 1 of every 21-day cycle. Patients were treated until disease progression or unacceptable toxicity. Tumor assessments, including brain-MRI in patients with presence or history of brain metastases at baseline, occurred every 6 weeks for the first 24 weeks and every 9 weeks thereafter. The major efficacy outcome measure was progression-free survival (PFS) in the first 480 randomized patients assessed by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Additional efficacy outcome measures were evaluated in all randomized patients and included overall survival (OS), PFS among patients with a history or presence of brain metastases (PFS BrainMets ), and confirmed objective response rate (ORR). The median age was 54 years (range: 22 - 82); 116 (19%) patients were age 65 or older. The majority were White (73%) and female (99%) and 51% had an ECOG performance status of 1. Sixty percent had estrogen and/or progesterone receptor-positive disease. Forty-eight percent had a presence or history of brain metastases; of these patients, 23% had untreated brain metastases, 40% had treated but stable brain metastases, and 37% had treated but radiographically progressing brain metastases. Seventy-four percent of patients had visceral metastases. Patients had received a median of 4 (range, 2 to 17) prior lines of systemic therapy and a median of 3 (range, 1 to 14) prior lines of systemic therapy in the metastatic setting. All patients received prior trastuzumab and T-DM1 and all but two patients had prior pertuzumab. Efficacy results are summarized in Table 12 and Figure 1 and 2. Efficacy results were consistent across patient subgroups defined by stratification factors (presence or history of brain metastases, ECOG status, region of world) and hormone receptor status. Table 12: Efficacy Results in HER2CLIMB BICR=blinded independent central review; CI=confidence interval; PFS=progression-free survival; OS=overall survival; ORR=objective response rate; CR=complete response; PR=partial response; DOR=duration of response. TUKYSA + Trastuzumab + Capecitabine Placebo + Trastuzumab + Capecitabine PFS Primary PFS analysis conducted in first 480 randomized patients. N=320 N=160 Number of events (%) 178 (56) 97 (61) Median, months (95% CI) 7.8 (7.5, 9.6) 5.6 (4.2, 7.1) Hazard ratio (95% CI) Hazard ratio and 95% confidence intervals are based on stratified Cox proportional hazards regression model controlling for stratification factors (presence or history of brain metastases, ECOG status, and region of world) 0.54 (0.42, 0.71) P-value Two-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.05 <0.00001 OS N=410 N=202 Number of deaths (%) 130 (32) 85 (42) Median, months (95% CI) 21.9 (18.3, 31.0) 17.4 (13.6, 19.9) Hazard ratio (95% CI) 0.66 (0.50, 0.87) P-value Two-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.0074 for this interim analysis (with 60% of the planned number of events for final analysis) 0.00480 PFS BrainMets Analysis includes patients with history or presence of parenchymal brain metastases at baseline, including target and non-target lesions. Does not include patients with dural lesions only. N=198 N=93 Number of events (%) 106 (53.5) 51 (54.8) Median, months (95% CI) 7.6 (6.2, 9.5) 5.4 (4.1, 5.7) Hazard ratio (95% CI) 0.48 (0.34, 0.69) P-value Two-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.0080 for this interim analysis (with 71% of the planned number of events for final analysis) <0.00001 Confirmed ORR for Patients with Measurable Disease N=340 N=171 ORR (95% CI) Two-sided 95% exact confidence interval, computed using the Clopper-Pearson method (1934) 40.6 (35.3, 46.0) 22.8 (16.7, 29.8) CR (%) 3 (0.9) 2 (1.2) PR (%) 135 (39.7) 37 (21.6) P-value 0.00008 DOR Median, months (95% CI) Calculated using the complementary log-log transformation method (Collett, 1994) 8.3 (6.2, 9.7) 6.3 (5.8, 8.9) figure 1 figure 2 14.2 HER2-Positive Metastatic Colorectal Cancer The efficacy of TUKYSA in combination with trastuzumab was evaluated in 84 patients in MOUNTAINEER (NCT03043313), an open-label, multicenter trial. Patients were required to have HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer and prior treatment with fluoropyrimidines, oxaliplatin, irinotecan, and anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb). Patients whose disease had deficient mismatch repair (dMMR) proteins or microsatellite instability-high (MSI-H) must have also received an anti-programmed cell death protein-1 (PD-1) mAb. Patients who received prior anti-HER2 targeting therapy were excluded. HER2 positivity as defined by HER2 overexpression or gene amplification was prospectively determined in local laboratories using immunohistochemistry (IHC), in situ hybridization (ISH), and/or next generation sequencing (NGS) on tumor tissue. RAS status was performed as standard of care prior to study entry based on expanded RAS testing including KRAS exons 2, 3, and 4 and NRAS exons 2, 3, and 4. The median age was 55 years (range: 24 to 77); 12 (14%) patients were age 65 or older. Seventy-seven percent of patients were White, 4% were Black, 4% were Asian, and 4% were Hispanic or Latino. Sixty-one percent of patients were male. Seventy percent of patients had lung metastases, 64% had liver metastases, 60% had an ECOG performance status of 0, 37% had an ECOG performance status of 1, and 4% had an ECOG performance status of 2. Ninety-nine percent of patients received prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan and 83% and 52% received anti-VEGF antibodies and anti-EGFR antibodies respectively; 23%, 38%, and 39% received 1, 2, or ≥3 prior lines of therapy, respectively. Patients received TUKYSA 300 mg orally twice per day with a loading dose of trastuzumab or a non-US approved trastuzumab product 8 mg/kg intravenously on Day 1 of Cycle 1, followed by a maintenance dose of trastuzumab 6 mg/kg on Day 1 of each subsequent 21-day cycle. Patients were treated until disease progression or unacceptable toxicity. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR) as assessed by blinded independent central review (BICR) according to RECIST version 1.1. Efficacy results are summarized in Table 13. Table 13: Efficacy Results in MOUNTAINEER TUKYSA + trastuzumab N=84 Overall Response Rate (%) (95% CI) 38 (28, 49) CR (%) 3 (3.6) PR (%) 29 (35) Duration of Response N=32 Median Based on Kaplan-Meier method. , months (95% CI) 12.4 (8.5, 20.5) Patients with DOR≥6 months Based on observed duration of response. 81% Patients with DOR≥12 months 34%"],"pharmacodynamics":["12.2 Pharmacodynamics Exposure Response Relationship Tucatinib exposure-response relationships and the time course of pharmacodynamics response have not been fully characterized. Cardiac Electrophysiology No large mean increase in QTc (i.e., > 20 ms) was detected following treatment with TUKYSA at the recommended dose of 300 mg taken orally twice daily."],"pharmacokinetics":["12.3 Pharmacokinetics Tucatinib AUC 0-INF and C max increased proportionally over a dosage range from 50 mg to 300 mg (0.17 to 1 times the approved recommended dosage). Time to steady state was approximately 4 days. Steady-state pharmacokinetic parameters following administration of TUKYSA 300 mg twice daily for 7 days in patients with mBC and mCRC are described in Table 9. The geometric mean (CV%) tucatinib AUC accumulation ratios ranged from 2.0 (26) fold to 2.5 (28) fold. Table 9: Tucatinib C max and AUC Tumor Type AUC ss (ng*h/mL) C max,ss (ng/mL) C trough,ss (ng/mL) mBC 5620 (43) 747 (45) 288 (59) mCRC 3370 (49) 405 (45) 197 (63) Absorption The median time to peak plasma concentration of tucatinib was approximately 2 hours (range 1 to 4 hours). Effects of Food Following administration of a single oral dose of TUKYSA in 11 subjects after a high-fat meal (approximately 58% fat, 26% carbohydrate, and 16% protein), the mean AUC 0-INF increased by 1.5-fold, the T max shifted from 1.5 hours to 4 hours, and C max was unaltered. The effect of food on the pharmacokinetics of tucatinib was not clinically meaningful. Distribution The geometric mean (CV%) apparent volume of distribution of tucatinib at steady-state were 903 (42) L and 829 (21) L in patients with mBC and mCRC, respectively. The plasma protein binding was 97.1% at clinically relevant concentrations. At steady-state, concentrations of tucatinib and its metabolite ONT-993 in the cerebrospinal fluid were comparable to unbound plasma concentrations. Elimination At steady-state, tucatinib effective half-life was approximately 11.9 hours and geometric mean (CV%) apparent clearance was 53 (43) L/h in patients with mBC. Tucatinib effective half-life was approximately 16.4 hours and geometric mean (CV%) apparent clearance was 89 (49) L/h in patients with mCRC. Metabolism Tucatinib is metabolized primarily by CYP2C8 and to a lesser extent via CYP3A. Excretion Following a single oral dose of 300 mg radiolabeled tucatinib, approximately 86% of the total radiolabeled dose was recovered in feces (16% of the administered dose as unchanged tucatinib) and 4.1% in urine with an overall total recovery of 90% within 13 days post-dose. In plasma, approximately 76% of the plasma radioactivity was unchanged, 19% was attributed to identified metabolites, and approximately 5% was unassigned. Specific Populations Age (18-77 years), albumin (19 to 52 g/L), creatinine clearance (CLcr: 60 to 89 mL/min (n = 63); CLcr 30 to 59 mL/min (n = 6)), body weight (41 to 146 kg), sex (male (n = 170), female (n = 113)) and race (White (n = 205), Black (n = 37), or Asian (n = 25)) did not have a clinically meaningful effect on tucatinib exposure. Renal Impairment No clinically significant differences in the pharmacokinetics of tucatinib were observed in patients with mild to moderate renal impairment (CLcr: 30 to 89 mL/min by Cockcroft-Gault). The effect of severe renal impairment (CLcr: < 30 mL/min) on the pharmacokinetics of tucatinib is unknown. Hepatic Impairment Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment had no clinically relevant effect on tucatinib exposure. Tucatinib AUC 0-INF was increased by 1.6 fold in subjects with severe (Child-Pugh C) hepatic impairment compared to subjects with normal hepatic function. Drug Interaction Studies Clinical Studies Table 10: Effect of Other Drugs on TUKYSA Concomitant Drug (Dose) TUKYSA Dose Ratio (90% CI) of Tucatinib Exposure With and Without Concomitant Drug C max AUC Strong CYP3A Inhibitor Itraconazole (200 mg BID) 300 mg single dose 1.3 (1.2, 1.4) 1.3 (1.3, 1.4) Strong CYP3A/Moderate 2C8 Inducer Rifampin (600 mg once daily) 0.6 (0.5, 0.8) 0.5 (0.4, 0.6) Strong CYP2C8 Inhibitor Gemfibrozil (600 mg BID) 1.6 (1.5, 1.8) 3.0 (2.7, 3.5) Table 11: Effect of TUKYSA on Other Drugs Concomitant Drug (Dose) TUKYSA Dose Ratio (90% CI) of Exposure Measures of Concomitant Drug with/without Tucatinib C max AUC CYP2C8 Substrate Repaglinide (0.5 mg single dose) 300 mg twice daily 1.7 (1.4, 2.1) 1.7 (1.5, 1.9) CYP3A Substrate Midazolam (2 mg single dose) 3.0 (2.6, 3.4) 5.7 (5.0, 6.5) P-gp Substrate Digoxin (0.5 mg single dose) 2.4 (1.9, 2.9) 1.5 (1.3, 1.7) MATE1/2-K substrate Tucatinib reduced the renal clearance of metformin without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C. Metformin (850 mg single dose) 1.1 (1.0, 1.2) 1.4 (1.2, 1.5) No clinically significant difference in the pharmacokinetics of tucatinib were observed when used concomitantly with omeprazole (proton pump inhibitor) or tolbutamide (sensitive CYP2C9 substrate). In Vitro Studies Cytochrome P450 (CYP) Enzymes: Tucatinib is a reversible inhibitor of CYP2C8 and CYP3A and a time-dependent inhibitor of CYP3A, but is not an inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6. Uridine diphosphate (UDP)-glucuronosyl transferase (UGT) Enzymes: Tucatinib is not an inhibitor of UGT1A1. Transporter Systems: Tucatinib is a substrate of P-gp and BCRP, but is not a substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, or BSEP. Tucatinib inhibits MATE1/MATE2-K-mediated transport of metformin and OCT2/MATE1-mediated transport of creatinine. The observed serum creatinine increase in clinical studies with tucatinib is due to inhibition of tubular secretion of creatinine via OCT2 and MATE1."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Diarrhea [see Warnings and Precautions (5.1) ] • Hepatotoxicity [see Warnings and Precautions (5.2) ] • The most common adverse reactions (≥20%) with TUKYSA in combination with trastuzumab and capecitabine in patients with metastatic breast cancer are diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash. ( 6.1 ) • The most common adverse reactions (≥20%) with TUKYSA in combination with trastuzumab in patients with unresectable or metastatic colorectal cancer are diarrhea, fatigue, rash, nausea, abdominal pain, infusion related reactions, and pyrexia. To report SUSPECTED ADVERSE REACTIONS, contact Seagen at 1-855-4SEAGEN or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. HER2-Positive Metastatic Breast Cancer The safety of TUKYSA in combination with trastuzumab and capecitabine was evaluated in HER2CLIMB [see Clinical Studies (14) ]. Patients received either TUKYSA 300 mg twice daily plus trastuzumab or a non-US approved trastuzumab product, and capecitabine (n=404) or placebo plus trastuzumab or a non-US approved trastuzumab product and capecitabine (n=197). The median duration of treatment was 5.8 months (range: 3 days, 2.9 years) for the TUKYSA arm. Serious adverse reactions occurred in 26% of patients who received TUKYSA. Serious adverse reactions in ≥ 2% of patients who received TUKYSA were diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and seizure (2%). Fatal adverse reactions occurred in 2% of patients who received TUKYSA including sudden death, sepsis, dehydration, and cardiogenic shock. Adverse reactions leading to treatment discontinuation occurred in 6% of patients who received TUKYSA. Adverse reactions leading to treatment discontinuation of TUKYSA in ≥1% of patients were hepatotoxicity (1.5%) and diarrhea (1%). Adverse reactions leading to dose reduction occurred in 21% of patients who received TUKYSA. Adverse reactions leading to dose reduction of TUKYSA in ≥2% of patients were hepatotoxicity (8%) and diarrhea (6%). The most common adverse reactions in patients who received TUKYSA (≥20%) were diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash. Table 3 summarizes the adverse reactions in HER2CLIMB. Table 3: Adverse Reactions (≥10%) in Patients Who Received TUKYSA and with a Difference Between Arms of ≥ 5% Compared to Placebo in HER2CLIMB (All Grades) Adverse Reaction TUKYSA + Trastuzumab + Capecitabine N = 404 Placebo + Trastuzumab + Capecitabine N = 197 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Gastrointestinal disorders Diarrhea 81 12 0.5 53 9 0 Nausea 58 3.7 0 44 3 0 Vomiting 36 3 0 25 3.6 0 Stomatitis Stomatitis includes stomatitis, oropharyngeal pain, oropharyngeal discomfort, mouth ulceration, oral pain, lip ulceration, glossodynia, tongue blistering, lip blister, oral dysesthesia, tongue ulceration, and aphthous ulcer 32 2.5 0 21 0.5 0 Skin and subcutaneous tissue disorders Palmar-plantar erythrodysesthesia syndrome 63 13 0 53 9 0 Rash Rash includes rash maculo-papular, rash, dermatitis acneiform, erythema, rash macular, rash papular, rash pustular, rash pruritic, rash erythematous, skin exfoliation, urticaria, dermatitis allergic, palmar erythema, plantar erythema, skin toxicity, and dermatitis 20 0.7 0 15 0.5 0 Hepatobiliary disorders Hepatotoxicity Hepatotoxicity includes hyperbilirubinemia, blood bilirubin increased, bilirubin conjugated increased, alanine aminotransferase increased, transaminases increased, hepatotoxicity, aspartate aminotransferase increased, liver function test increased, liver injury, and hepatocellular injury 42 9 0.2 24 3.6 0 Metabolism and nutrition disorders Decreased appetite 25 0.5 0 20 0 0 Blood and lymphatic system disorders Anemia Anemia includes anemia, hemoglobin decreased, and normocytic anemia 21 3.7 0 13 2.5 0 Musculoskeletal and connective tissue disorders Arthralgia 15 0.5 0 4.6 0.5 0 Investigations Creatinine increased Due to inhibition of renal tubular transport of creatinine without affecting glomerular function 14 0 0 1.5 0 0 Weight decreased 13 1 0 6 0.5 0 Nervous System Disorders Peripheral neuropathy Peripheral neuropathy includes peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy 13 0.5 0 7 1 0 Respiratory, thoracic and mediastinal disorders Epistaxis 12 0 0 5 0 0 Table 4: Laboratory Abnormalities (≥20%) Worsening from Baseline in Patients Who Received TUKYSA and with a Difference of ≥5% Compared to Placebo in HER2CLIMB Laboratory Abnormality TUKYSA + Trastuzumab +Capecitabine The denominator used to calculate the rate varied from 351 to 400 in the TUKYSA arm and 173 to 197 in the control arm based on the number of patients with a baseline value and at least one post-treatment value. Grading was based on NCI-CTCAE v.4.03 for laboratory abnormalities, except for increased creatinine which only includes patients with a creatinine increase based on the upper limit of normal definition for grade 1 events (NCI CTCAE v5.0). Placebo + Trastuzumab +Capecitabine All Grades % Grades ≥3 % All Grades % Grades ≥3 % Hematology Decreased hemoglobin 59 3.3 51 1.5 Chemistry Decreased phosphate 57 8 45 7 Increased bilirubin 47 1.5 30 3.1 Increased ALT 46 8 27 0.5 Increased AST 43 6 25 1 Decreased magnesium 40 0.8 25 0.5 Decreased potassium Laboratory criteria for Grade 1 is identical to laboratory criteria for Grade 2. 36 6 31 5 Increased creatinine Due to inhibition of renal tubular transport of creatinine without affecting glomerular function. 33 0 6 0 Decreased sodium There is no definition for Grade 2 in CTCAE v.4.03. 28 2.5 23 2 Increased alkaline phosphatase 26 0.5 17 0 Increased Creatinine The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed [see Clinical Pharmacology (12.3) ] . RAS Wild-Type, HER2-Positive Unresectable or Metastatic Colorectal Cancer The safety of TUKYSA in combination with trastuzumab or a non-US approved trastuzumab product was evaluated in 86 patients enrolled in MOUNTAINEER with unresectable or metastatic colorectal cancer [see Clinical Studies (14.2) ] . The median duration of exposure to TUKYSA was 6.9 months (range 0.7, 49.3). Serious adverse reactions occurred in 22% of patients. Serious adverse reactions that occurred in ≥ 2% of patients were intestinal obstruction (7%), urinary tract infection (3.5%), pneumonia (2.3%), abdominal pain (2.3%) and rectal perforation (2.3%). Permanent discontinuation of TUKYSA due to an adverse reaction occurred in 6% of patients. The adverse reaction which resulted in permanent discontinuation of TUKYSA in ≥2% of patients was increased ALT (2.3%). Dosage interruptions of TUKYSA due to an adverse reaction occurred in 23% of patients. Adverse reactions which required dosage interruption in ≥3% of patients were increased ALT (3.5%) and diarrhea (3.5%). Dose reductions of TUKYSA due to an adverse reaction occurred in 9% of patients. Adverse reactions which required dose reductions in ≥2% of patients were increased ALT (2.3%) and diarrhea (2.3%). The most common adverse reactions reported in ≥ 20% of patients treated with TUKYSA and trastuzumab were diarrhea, fatigue, rash, nausea, abdominal pain, infusion related reactions, and pyrexia. The most common laboratory abnormalities reported in ≥ 20% of patients were increased creatinine, increased glucose, increased ALT, decreased hemoglobin, increased AST, increased bilirubin, increased alkaline phosphatase, decreased lymphocytes, decreased albumin, decreased leukocytes, and decreased sodium. Table 5 summarizes the adverse reactions in MOUNTAINEER. Table 5: Adverse Reactions (≥10%) in Patients with Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER) Adverse Reaction TUKYSA + Trastuzumab N= 86 Includes 1 patient who only received trastuzumab. All Grades % Grade 3 % Gastrointestinal disorders Diarrhea 64 3.5 Nausea 35 0 Vomiting 16 0 Abdominal pain Abdominal pain includes abdominal discomfort, abdominal pain, and abdominal pain upper. 21 2.3 Constipation 14 1.2 General disorders Fatigue 44 2.3 Pyrexia 20 0 Chills 19 1.2 Skin and subcutaneous disorders Rash Rash includes acne, dermatitis acneiform, dermatitis contact, erythema, erythema multiforme, rash, rash macular, rash maculo-papular, rash papular, rash pustular, skin exfoliation, and urticaria. 37 0 Injury, poisoning, and procedural complications Infusion related reaction 21 0 Metabolism and nutrition disorders Decreased appetite 19 0 Blood and lymphatic system disorders Anemia 10 0 Vascular disorders Hypertension 17 7 Musculoskeletal and connective tissue disorders Back pain 17 2.3 Arthralgia 16 1.2 Myalgia 13 0 Respiratory, thoracic and mediastinal disorders Cough 16 0 Dyspnea 14 0 Psychiatric disorders Anxiety 10 0 Other adverse reactions (<10%) include epistaxis (7%), weight decreased (7%), oropharyngeal pain (5%), oral dysesthesia (1%), and stomatitis (1%). Table 6: Laboratory Abnormalities (≥15%) Worsening from Baseline in Patients with Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER) Laboratory Abnormality TUKYSA + Trastuzumab N=85 Number of patients with both baseline and post-baseline results for each test All Grades % Grade 3 % Grade 4 % Hematology Decreased hemoglobin 46 3.5 0 Decreased lymphocytes 39 12 0 Decreased leukocytes 22 0 0 Decreased platelets 15 0 0 Chemistry Increased creatinine NCI CTCAE v5.0 was used for creatinine increased. NCI CTCAE v4.03 was used for all other laboratory parameters. , Due to inhibition of renal tubular transport of creatinine without affecting glomerular function 58 0 0 Increased glucose 56 2.4 0 Increased ALT 46 2.4 2.4 Increased AST 33 2.4 3.5 Increased bilirubin 28 3.5 2.4 Increased alkaline phosphatase 25 1.2 0 Decreased albumin 24 1.2 0 Decreased sodium 20 6 0 Decreased potassium 16 1.2 0 Increased Creatinine The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible in 87% of patients with values outside normal lab limits upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed [see Clinical Pharmacology (12.3) ] ."],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS • Strong CYP3A Inducers or Moderate CYP2C8 Inducers : Avoid concomitant use. ( 7.1 ) • Strong CYP2C8 Inhibitors : Avoid concomitant use; reduce TUKYSA dose if concomitant use cannot be avoided. ( 2.4 , 7.1 ) • CYP3A Substrates : Avoid concomitant use with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. ( 7.2 ) • P-gp Substrates : Consider reducing the dose of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. ( 7.2 ) 7.1 Effects of Other Drugs on TUKYSA Table 7 summarizes the effect of other drugs on TUKYSA. Table 7: Drug Interactions that Affect TUKYSA Strong CYP3A Inducers or Moderate CYP2C8 Inducers Clinical Impact Concomitant use of TUKYSA with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib plasma concentrations [see Clinical Pharmacology (12.3) ] , which may reduce TUKYSA activity. Management Avoid concomitant use of TUKYSA with a strong CYP3A inducer or a moderate CYP2C8 inducer. Strong or Moderate CYP2C8 Inhibitors Clinical Impact Concomitant use of TUKYSA with a strong CYP2C8 inhibitor increased tucatinib plasma concentrations [see Clinical Pharmacology (12.3) ] , which may increase the risk of TUKYSA toxicity. Management Avoid concomitant use of TUKYSA with a strong CYP2C8 inhibitor. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors. 7.2 Effects of TUKYSA on Other Drugs Table 8 summarizes the effect of TUKYSA on other drugs. Table 8: TUKYSA Drug Interactions that Affect Other Drugs CYP3A Substrates Clinical Impact Concomitant use of TUKYSA with a CYP3A substrate increased the plasma concentrations of CYP3A substrate [see Clinical Pharmacology (12.3) ] , which may increase the toxicity associated with a CYP3A substrate. Management Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling. P-glycoprotein (P-gp) Substrates Clinical Impact Concomitant use of TUKYSA with a P-gp substrate increased the plasma concentrations of P-gp substrate [see Clinical Pharmacology (12.3) ] , which may increase the toxicity associated with a P-gp substrate. Management Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities."],"mechanism_of_action":["12.1 Mechanism of Action Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo, tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone."],"recent_major_changes":["Indications and Usage ( 1.2 ) 1/2023 Patient Selection ( 2.1 ) 1/2023 Warnings and Precautions ( 5.1 ), ( 5.2 ) 1/2023"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo, tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone. 12.2 Pharmacodynamics Exposure Response Relationship Tucatinib exposure-response relationships and the time course of pharmacodynamics response have not been fully characterized. Cardiac Electrophysiology No large mean increase in QTc (i.e., > 20 ms) was detected following treatment with TUKYSA at the recommended dose of 300 mg taken orally twice daily. 12.3 Pharmacokinetics Tucatinib AUC 0-INF and C max increased proportionally over a dosage range from 50 mg to 300 mg (0.17 to 1 times the approved recommended dosage). Time to steady state was approximately 4 days. Steady-state pharmacokinetic parameters following administration of TUKYSA 300 mg twice daily for 7 days in patients with mBC and mCRC are described in Table 9. The geometric mean (CV%) tucatinib AUC accumulation ratios ranged from 2.0 (26) fold to 2.5 (28) fold. Table 9: Tucatinib C max and AUC Tumor Type AUC ss (ng*h/mL) C max,ss (ng/mL) C trough,ss (ng/mL) mBC 5620 (43) 747 (45) 288 (59) mCRC 3370 (49) 405 (45) 197 (63) Absorption The median time to peak plasma concentration of tucatinib was approximately 2 hours (range 1 to 4 hours). Effects of Food Following administration of a single oral dose of TUKYSA in 11 subjects after a high-fat meal (approximately 58% fat, 26% carbohydrate, and 16% protein), the mean AUC 0-INF increased by 1.5-fold, the T max shifted from 1.5 hours to 4 hours, and C max was unaltered. The effect of food on the pharmacokinetics of tucatinib was not clinically meaningful. Distribution The geometric mean (CV%) apparent volume of distribution of tucatinib at steady-state were 903 (42) L and 829 (21) L in patients with mBC and mCRC, respectively. The plasma protein binding was 97.1% at clinically relevant concentrations. At steady-state, concentrations of tucatinib and its metabolite ONT-993 in the cerebrospinal fluid were comparable to unbound plasma concentrations. Elimination At steady-state, tucatinib effective half-life was approximately 11.9 hours and geometric mean (CV%) apparent clearance was 53 (43) L/h in patients with mBC. Tucatinib effective half-life was approximately 16.4 hours and geometric mean (CV%) apparent clearance was 89 (49) L/h in patients with mCRC. Metabolism Tucatinib is metabolized primarily by CYP2C8 and to a lesser extent via CYP3A. Excretion Following a single oral dose of 300 mg radiolabeled tucatinib, approximately 86% of the total radiolabeled dose was recovered in feces (16% of the administered dose as unchanged tucatinib) and 4.1% in urine with an overall total recovery of 90% within 13 days post-dose. In plasma, approximately 76% of the plasma radioactivity was unchanged, 19% was attributed to identified metabolites, and approximately 5% was unassigned. Specific Populations Age (18-77 years), albumin (19 to 52 g/L), creatinine clearance (CLcr: 60 to 89 mL/min (n = 63); CLcr 30 to 59 mL/min (n = 6)), body weight (41 to 146 kg), sex (male (n = 170), female (n = 113)) and race (White (n = 205), Black (n = 37), or Asian (n = 25)) did not have a clinically meaningful effect on tucatinib exposure. Renal Impairment No clinically significant differences in the pharmacokinetics of tucatinib were observed in patients with mild to moderate renal impairment (CLcr: 30 to 89 mL/min by Cockcroft-Gault). The effect of severe renal impairment (CLcr: < 30 mL/min) on the pharmacokinetics of tucatinib is unknown. Hepatic Impairment Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment had no clinically relevant effect on tucatinib exposure. Tucatinib AUC 0-INF was increased by 1.6 fold in subjects with severe (Child-Pugh C) hepatic impairment compared to subjects with normal hepatic function. Drug Interaction Studies Clinical Studies Table 10: Effect of Other Drugs on TUKYSA Concomitant Drug (Dose) TUKYSA Dose Ratio (90% CI) of Tucatinib Exposure With and Without Concomitant Drug C max AUC Strong CYP3A Inhibitor Itraconazole (200 mg BID) 300 mg single dose 1.3 (1.2, 1.4) 1.3 (1.3, 1.4) Strong CYP3A/Moderate 2C8 Inducer Rifampin (600 mg once daily) 0.6 (0.5, 0.8) 0.5 (0.4, 0.6) Strong CYP2C8 Inhibitor Gemfibrozil (600 mg BID) 1.6 (1.5, 1.8) 3.0 (2.7, 3.5) Table 11: Effect of TUKYSA on Other Drugs Concomitant Drug (Dose) TUKYSA Dose Ratio (90% CI) of Exposure Measures of Concomitant Drug with/without Tucatinib C max AUC CYP2C8 Substrate Repaglinide (0.5 mg single dose) 300 mg twice daily 1.7 (1.4, 2.1) 1.7 (1.5, 1.9) CYP3A Substrate Midazolam (2 mg single dose) 3.0 (2.6, 3.4) 5.7 (5.0, 6.5) P-gp Substrate Digoxin (0.5 mg single dose) 2.4 (1.9, 2.9) 1.5 (1.3, 1.7) MATE1/2-K substrate Tucatinib reduced the renal clearance of metformin without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C. Metformin (850 mg single dose) 1.1 (1.0, 1.2) 1.4 (1.2, 1.5) No clinically significant difference in the pharmacokinetics of tucatinib were observed when used concomitantly with omeprazole (proton pump inhibitor) or tolbutamide (sensitive CYP2C9 substrate). In Vitro Studies Cytochrome P450 (CYP) Enzymes: Tucatinib is a reversible inhibitor of CYP2C8 and CYP3A and a time-dependent inhibitor of CYP3A, but is not an inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6. Uridine diphosphate (UDP)-glucuronosyl transferase (UGT) Enzymes: Tucatinib is not an inhibitor of UGT1A1. Transporter Systems: Tucatinib is a substrate of P-gp and BCRP, but is not a substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, or BSEP. Tucatinib inhibits MATE1/MATE2-K-mediated transport of metformin and OCT2/MATE1-mediated transport of creatinine. The observed serum creatinine increase in clinical studies with tucatinib is due to inhibition of tubular secretion of creatinine via OCT2 and MATE1."],"indications_and_usage":["1 INDICATIONS AND USAGE TUKYSA is a kinase inhibitor indicated: • in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. ( 1.1 ) • in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 1.1 Metastatic Breast Cancer TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. 1.2 Unresectable or Metastatic Colorectal Cancer TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Diarrhea : Severe diarrhea, including dehydration, acute kidney injury, and death, has been reported. Administer antidiarrheal treatment as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue TUKYSA based on severity. ( 2.2 , 5.1 ) • Hepatotoxicity : Severe hepatotoxicity has been reported on TUKYSA. Monitor ALT, AST and bilirubin prior to starting TUKYSA, every 3 weeks during treatment and as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue TUKYSA based on severity. ( 2.2 , 5.2 ) • Embryo-Fetal Toxicity : TUKYSA can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.3 , 8.1 , 8.3 ) Also, refer to the Full Prescribing Information of trastuzumab and capecitabine for pregnancy and contraception information. 5.1 Diarrhea TUKYSA can cause severe diarrhea including dehydration, hypotension, acute kidney injury, and death [see Adverse Reactions (6.1) ] . If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Based on the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue TUKYSA [see Dosage and Administration (2.2) ] . TUKYSA with trastuzumab and capecitabine In HER2CLIMB, 81% of patients who received TUKYSA experienced diarrhea, including 0.5% with Grade 4 diarrhea and 12% with Grade 3 diarrhea. Both patients who developed Grade 4 diarrhea subsequently died, with diarrhea as a contributor to death. The median time to onset of the first episode of diarrhea was 12 days and the median time to resolution was 8 days. Diarrhea led to dose reductions of TUKYSA in 6% of patients and discontinuation of TUKYSA in 1% of patients. Prophylactic use of antidiarrheal treatment was not required on HER2CLIMB. TUKYSA with trastuzumab In MOUNTAINEER, diarrhea occurred in 64% of patients, including Grade 3 (3.5%), Grade 2 (10%), and Grade 1 (50%). 5.2 Hepatotoxicity TUKYSA can cause severe hepatotoxicity [see Adverse Reactions (6.1) ] . Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA [see Dosage and Administration (2.2) ] . TUKYSA with trastuzumab and capecitabine In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase > 5 × ULN, 6% had an AST increase > 5 × ULN, and 1.5% had a bilirubin increase > 3 × ULN (Grade ≥3). Hepatotoxicity led to dose reduction of TUKYSA in 8% of patients and discontinuation of TUKYSA in 1.5% of patients. TUKYSA with trastuzumab In MOUNTAINEER, 6% of patients had a bilirubin increase > 3 × ULN (Grade ≥3), 6% had an AST increase > 5 × ULN, and 4.7% had an ALT increase > 5 × ULN. Hepatotoxicity led to dose reduction of TUKYSA in 3.5% of patients and discontinuation of TUKYSA in 2.3% of patients. 5.3 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, TUKYSA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of tucatinib to pregnant rats and rabbits during organogenesis caused embryo-fetal mortality, reduced fetal weight and fetal abnormalities at maternal exposures ≥ 1.3 times the human exposure (AUC) at the recommended dose. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose [see Use in Specific Populations (8.1 , 8.3 )] . TUKYSA is used in combination with trastuzumab and capecitabine. Refer to the Full Prescribing Information of trastuzumab and capecitabine for pregnancy and contraception information."],"clinical_studies_table":["
Table 12: Efficacy Results in HER2CLIMB
BICR=blinded independent central review; CI=confidence interval; PFS=progression-free survival; OS=overall survival; ORR=objective response rate; CR=complete response; PR=partial response; DOR=duration of response.
TUKYSA + Trastuzumab + CapecitabinePlacebo + Trastuzumab + Capecitabine
PFSPrimary PFS analysis conducted in first 480 randomized patients.N=320N=160
Number of events (%)178 (56)97 (61)
Median, months (95% CI)7.8 (7.5, 9.6)5.6 (4.2, 7.1)
Hazard ratio (95% CI)Hazard ratio and 95% confidence intervals are based on stratified Cox proportional hazards regression model controlling for stratification factors (presence or history of brain metastases, ECOG status, and region of world)0.54 (0.42, 0.71)
P-valueTwo-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.05<0.00001
OSN=410N=202
Number of deaths (%)130 (32)85 (42)
Median, months (95% CI)21.9 (18.3, 31.0)17.4 (13.6, 19.9)
Hazard ratio (95% CI)0.66 (0.50, 0.87)
P-valueTwo-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.0074 for this interim analysis (with 60% of the planned number of events for final analysis)0.00480
PFSBrainMetsAnalysis includes patients with history or presence of parenchymal brain metastases at baseline, including target and non-target lesions. Does not include patients with dural lesions only.N=198N=93
Number of events (%)106 (53.5)51 (54.8)
Median, months (95% CI)7.6 (6.2, 9.5)5.4 (4.1, 5.7)
Hazard ratio (95% CI)0.48 (0.34, 0.69)
P-valueTwo-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.0080 for this interim analysis (with 71% of the planned number of events for final analysis)<0.00001
Confirmed ORR for Patients with Measurable DiseaseN=340N=171
ORR (95% CI)Two-sided 95% exact confidence interval, computed using the Clopper-Pearson method (1934)40.6 (35.3, 46.0)22.8 (16.7, 29.8)
CR (%)3 (0.9)2 (1.2)
PR (%)135 (39.7)37 (21.6)
P-value0.00008
DOR
Median, months (95% CI)Calculated using the complementary log-log transformation method (Collett, 1994)8.3 (6.2, 9.7)6.3 (5.8, 8.9)
","
Table 13: Efficacy Results in MOUNTAINEER
TUKYSA + trastuzumab N=84
Overall Response Rate (%) (95% CI)38 (28, 49)
CR (%)3 (3.6)
PR (%)29 (35)
Duration of ResponseN=32
MedianBased on Kaplan-Meier method., months (95% CI)12.4 (8.5, 20.5)
Patients with DOR≥6 monthsBased on observed duration of response.81%
Patients with DOR≥12 months34%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with tucatinib. Tucatinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay. Tucatinib was not clastogenic in either an in vitro chromosome aberration assay or an in vivo mouse bone marrow micronucleus assay. Fertility studies in animals have not been conducted. In repeat-dose toxicity studies up to 13 weeks duration, decreased corpora lutea/corpus luteum cyst, increased interstitial cells of the ovary, atrophy of the uterus, and mucification of the vagina were observed in female rats at doses ≥ 6 mg/kg/day (approximately 0.1 times the human exposure at the recommended dose based on AUC). Atrophy and edema of the testes and oligospermia/germ cell debris in the epididymides were observed in male rats at ≥ 120 mg/kg/day (approximately 13 times the human exposure at the recommended dose based on AUC)."],"pharmacokinetics_table":["
Table 9: Tucatinib Cmax and AUC
Tumor TypeAUCss (ng*h/mL)Cmax,ss (ng/mL)Ctrough,ss (ng/mL)
mBC5620 (43)747 (45)288 (59)
mCRC3370 (49)405 (45)197 (63)
","
Table 10: Effect of Other Drugs on TUKYSA
Concomitant Drug (Dose)TUKYSA DoseRatio (90% CI) of Tucatinib Exposure With and Without Concomitant Drug
CmaxAUC
Strong CYP3A Inhibitor Itraconazole (200 mg BID)300 mg single dose1.3 (1.2, 1.4)1.3 (1.3, 1.4)
Strong CYP3A/Moderate 2C8 Inducer Rifampin (600 mg once daily)0.6 (0.5, 0.8)0.5 (0.4, 0.6)
Strong CYP2C8 Inhibitor Gemfibrozil (600 mg BID)1.6 (1.5, 1.8)3.0 (2.7, 3.5)
","
Table 11: Effect of TUKYSA on Other Drugs
Concomitant Drug (Dose)TUKYSA DoseRatio (90% CI) of Exposure Measures of Concomitant Drug with/without Tucatinib
CmaxAUC
CYP2C8 Substrate Repaglinide (0.5 mg single dose)300 mg twice daily1.7 (1.4, 2.1)1.7 (1.5, 1.9)
CYP3A Substrate Midazolam (2 mg single dose)3.0 (2.6, 3.4)5.7 (5.0, 6.5)
P-gp Substrate Digoxin (0.5 mg single dose)2.4 (1.9, 2.9)1.5 (1.3, 1.7)
MATE1/2-K substrateTucatinib reduced the renal clearance of metformin without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C. Metformin (850 mg single dose)1.1 (1.0, 1.2)1.4 (1.2, 1.5)
"],"adverse_reactions_table":["
Table 3: Adverse Reactions (≥10%) in Patients Who Received TUKYSA and with a Difference Between Arms of ≥ 5% Compared to Placebo in HER2CLIMB (All Grades)
Adverse ReactionTUKYSA + Trastuzumab + CapecitabineN = 404Placebo + Trastuzumab + CapecitabineN = 197
All Grades%Grade 3%Grade 4%All Grades%Grade 3%Grade 4%
Gastrointestinal disorders
Diarrhea81120.55390
Nausea583.704430
Vomiting 3630253.60
StomatitisStomatitis includes stomatitis, oropharyngeal pain, oropharyngeal discomfort, mouth ulceration, oral pain, lip ulceration, glossodynia, tongue blistering, lip blister, oral dysesthesia, tongue ulceration, and aphthous ulcer322.50210.50
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysesthesia syndrome631305390
RashRash includes rash maculo-papular, rash, dermatitis acneiform, erythema, rash macular, rash papular, rash pustular, rash pruritic, rash erythematous, skin exfoliation, urticaria, dermatitis allergic, palmar erythema, plantar erythema, skin toxicity, and dermatitis200.70150.50
Hepatobiliary disorders
HepatotoxicityHepatotoxicity includes hyperbilirubinemia, blood bilirubin increased, bilirubin conjugated increased, alanine aminotransferase increased, transaminases increased, hepatotoxicity, aspartate aminotransferase increased, liver function test increased, liver injury, and hepatocellular injury4290.2243.60
Metabolism and nutrition disorders
Decreased appetite250.502000
Blood and lymphatic system disorders
AnemiaAnemia includes anemia, hemoglobin decreased, and normocytic anemia213.70132.50
Musculoskeletal and connective tissue disorders
Arthralgia150.504.60.50
Investigations
Creatinine increasedDue to inhibition of renal tubular transport of creatinine without affecting glomerular function14001.500
Weight decreased131060.50
Nervous System Disorders
Peripheral neuropathyPeripheral neuropathy includes peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy130.50710
Respiratory, thoracic and mediastinal disorders
Epistaxis1200500
","
Table 4: Laboratory Abnormalities (≥20%) Worsening from Baseline in Patients Who Received TUKYSA and with a Difference of ≥5% Compared to Placebo in HER2CLIMB
Laboratory AbnormalityTUKYSA + Trastuzumab +CapecitabineThe denominator used to calculate the rate varied from 351 to 400 in the TUKYSA arm and 173 to 197 in the control arm based on the number of patients with a baseline value and at least one post-treatment value. Grading was based on NCI-CTCAE v.4.03 for laboratory abnormalities, except for increased creatinine which only includes patients with a creatinine increase based on the upper limit of normal definition for grade 1 events (NCI CTCAE v5.0).Placebo + Trastuzumab +Capecitabine
All Grades%Grades ≥3%All Grades%Grades ≥3%
Hematology
Decreased hemoglobin593.3511.5
Chemistry
Decreased phosphate578457
Increased bilirubin471.5303.1
Increased ALT468270.5
Increased AST436251
Decreased magnesium400.8250.5
Decreased potassiumLaboratory criteria for Grade 1 is identical to laboratory criteria for Grade 2.366315
Increased creatinineDue to inhibition of renal tubular transport of creatinine without affecting glomerular function.33060
Decreased sodiumThere is no definition for Grade 2 in CTCAE v.4.03.282.5232
Increased alkaline phosphatase260.5170
","
Table 5: Adverse Reactions (≥10%) in Patients with Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER)
Adverse ReactionTUKYSA + TrastuzumabN= 86Includes 1 patient who only received trastuzumab.
All Grades%Grade 3%
Gastrointestinal disorders
Diarrhea643.5
Nausea350
Vomiting160
Abdominal painAbdominal pain includes abdominal discomfort, abdominal pain, and abdominal pain upper.212.3
Constipation141.2
General disorders
Fatigue442.3
Pyrexia200
Chills191.2
Skin and subcutaneous disorders
RashRash includes acne, dermatitis acneiform, dermatitis contact, erythema, erythema multiforme, rash, rash macular, rash maculo-papular, rash papular, rash pustular, skin exfoliation, and urticaria.370
Injury, poisoning, and procedural complications
Infusion related reaction210
Metabolism and nutrition disorders
Decreased appetite190
Blood and lymphatic system disorders
Anemia100
Vascular disorders
Hypertension177
Musculoskeletal and connective tissue disorders
Back pain172.3
Arthralgia161.2
Myalgia130
Respiratory, thoracic and mediastinal disorders
Cough160
Dyspnea140
Psychiatric disorders
Anxiety100
","
Table 6: Laboratory Abnormalities (≥15%) Worsening from Baseline in Patients with Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER)
Laboratory AbnormalityTUKYSA + TrastuzumabN=85Number of patients with both baseline and post-baseline results for each test
All Grades%Grade 3%Grade 4%
Hematology
Decreased hemoglobin463.50
Decreased lymphocytes39120
Decreased leukocytes2200
Decreased platelets1500
Chemistry
Increased creatinineNCI CTCAE v5.0 was used for creatinine increased. NCI CTCAE v4.03 was used for all other laboratory parameters.,Due to inhibition of renal tubular transport of creatinine without affecting glomerular function5800
Increased glucose562.40
Increased ALT462.42.4
Increased AST332.43.5
Increased bilirubin283.52.4
Increased alkaline phosphatase251.20
Decreased albumin241.20
Decreased sodium2060
Decreased potassium161.20
"],"drug_interactions_table":["
Table 7: Drug Interactions that Affect TUKYSA
Strong CYP3A Inducers or Moderate CYP2C8 Inducers
Clinical ImpactConcomitant use of TUKYSA with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib plasma concentrations [see Clinical Pharmacology (12.3)], which may reduce TUKYSA activity.
ManagementAvoid concomitant use of TUKYSA with a strong CYP3A inducer or a moderate CYP2C8 inducer.
Strong or Moderate CYP2C8 Inhibitors
Clinical ImpactConcomitant use of TUKYSA with a strong CYP2C8 inhibitor increased tucatinib plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of TUKYSA toxicity.
ManagementAvoid concomitant use of TUKYSA with a strong CYP2C8 inhibitor. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
","
Table 8: TUKYSA Drug Interactions that Affect Other Drugs
CYP3A Substrates
Clinical ImpactConcomitant use of TUKYSA with a CYP3A substrate increased the plasma concentrations of CYP3A substrate [see Clinical Pharmacology (12.3)], which may increase the toxicity associated with a CYP3A substrate.
ManagementAvoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling.
P-glycoprotein (P-gp) Substrates
Clinical ImpactConcomitant use of TUKYSA with a P-gp substrate increased the plasma concentrations of P-gp substrate [see Clinical Pharmacology (12.3)], which may increase the toxicity associated with a P-gp substrate.
ManagementConsider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Diarrhea • Inform patients that TUKYSA has been associated with severe diarrhea. Instruct patients on how to manage diarrhea and to inform their healthcare provider immediately if there is any change in bowel patterns [see Warnings and Precautions (5.1) ] . Hepatotoxicity • Inform patients that TUKYSA has been associated with severe hepatotoxicity and that they should report signs and symptoms of liver dysfunction to their healthcare provider immediately [see Warnings and Precautions (5.2) ] . Embryo-Fetal Toxicity • Inform pregnant women and females of reproductive potential of the risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1) ]. • Advise females of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose [see Use in Specific Populations (8.3) ] . • Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose [see Use in Specific Populations (8.3) ] . • Refer to the Full Prescribing Information of trastuzumab and capecitabine for pregnancy and contraception information. Lactation • Advise women not to breastfeed during treatment with TUKYSA and for 1 week after the last dose [see Use in Specific Populations (8.2) ] . Refer to the Full Prescribing Information of trastuzumab and capecitabine for lactation information. Infertility • Advise males and females of reproductive potential that TUKYSA may impair fertility [see Use in Specific Populations (8.3) ] . Refer to the Full Prescribing Information of trastuzumab and capecitabine for infertility information. Manufactured for: Seagen Inc. Bothell, WA 98021 1-855-4SEAGEN TUKYSA, Seagen, and are US registered trademarks of Seagen Inc. © 2023 Seagen Inc., Bothell, WA 98021. All rights reserved. USPI-213411-v04 logo small logo"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • In patients with unresectable or metastatic colorectal cancer, confirm the presence of HER2 protein overexpression and RAS wild-type in tumor specimens prior to the initiation of TUKYSA ( 2.1 ) • Recommended dosage: 300 mg taken orally twice daily with or without food. ( 2.1 ) • For patients with severe hepatic impairment, the recommended dosage is 200 mg orally twice daily. ( 2.3 , 8.7 ) 2.1 Patient Selection Select patients for treatment of unresectable or metastatic colorectal cancer with TUKYSA based on the presence of: • HER2 overexpression or gene amplification [see Clinical Studies (14.2) ]. FDA-approved tests for the detection of HER2 overexpression and gene amplification in patients with unresectable or metastatic colorectal cancer are not currently available, and • RAS wild-type [see Clinical Studies (14.2) ]. Information on FDA-approved tests for the detection of RAS mutations in patients with unresectable or metastatic colorectal cancer is available at http://www.fda.gov/CompanionDiagnostics . 2.2 Recommended Dosage Metastatic Breast Cancer The recommended dosage of TUKYSA is 300 mg taken orally twice daily in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity [see Clinical Studies (14.1) ] . Unresectable or Metastatic Colorectal Cancer The recommended dosage of TUKYSA is 300 mg taken orally twice daily in combination with trastuzumab until disease progression or unacceptable toxicity [see Clinical Studies (14.2) ]. Advise patients to swallow TUKYSA tablets whole and not to chew, crush, or split prior to swallowing. Advise patients not to ingest tablet if it is broken, cracked, or not otherwise intact. Advise patients to take TUKYSA approximately 12 hours apart and at the same time each day with or without a meal. If the patient vomits or misses a dose of TUKYSA, instruct the patient to take the next dose at its usual scheduled time. When given in combination with TUKYSA, the recommended dosage of capecitabine is 1000 mg/m 2 orally twice daily taken within 30 minutes after a meal. TUKYSA and capecitabine can be taken at the same time. Refer to the Full Prescribing Information for trastuzumab and capecitabine for additional information. 2.3 Dosage Modifications for Adverse Reactions The recommended TUKYSA dose reductions and dosage modifications for adverse reactions are provided in Tables 1 and 2. Refer to the Full Prescribing Information for trastuzumab and capecitabine for information about dosage modifications for these drugs. Table 1: Recommended TUKYSA Dose Reductions for Adverse Reactions Dose Reduction Recommended TUKYSA Dosage First 250 mg orally twice daily Second 200 mg orally twice daily Third 150 mg orally twice daily Permanently discontinue TUKYSA in patients unable to tolerate 150 mg orally twice daily. Table 2: Recommended TUKYSA Dosage Modifications for Adverse Reactions Adverse Reaction Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 Severity TUKYSA Dosage Modification Diarrhea [see Warnings and Precautions (5.1) ] Grade 3 without anti-diarrheal treatment Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose level. Grade 3 with anti-diarrheal treatment Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level. Grade 4 Permanently discontinue TUKYSA. Hepatotoxicity Abbreviations: ULN = upper limit of normal; ALT = alanine aminotransferase; AST = aspartate aminotransferase [see Warnings and Precautions (5.2) ] Grade 2 bilirubin (>1.5 to 3 × ULN) Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose level. Grade 3 ALT or AST (> 5 to 20 × ULN) OR Grade 3 bilirubin (> 3 to 10 × ULN) Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level. Grade 4 ALT or AST (> 20 × ULN) OR Grade 4 bilirubin (> 10 × ULN) Permanently discontinue TUKYSA. ALT or AST > 3 × ULN AND Bilirubin > 2 × ULN Permanently discontinue TUKYSA. Other adverse reactions [see Adverse Reactions (6.1) ] Grade 3 Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level. Grade 4 Permanently discontinue TUKYSA. 2.4 Dosage Modifications for Severe Hepatic Impairment For patients with severe hepatic impairment (Child-Pugh C), reduce the recommended dosage to 200 mg orally twice daily [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . 2.5 Dosage Modifications for Concomitant Use with Strong CYP2C8 Inhibitors Avoid concomitant use of strong CYP2C8 inhibitors with TUKYSA. If concomitant use with a strong CYP2C8 inhibitor cannot be avoided, reduce the recommended dosage to 100 mg orally twice daily. After discontinuation of the strong CYP2C8 inhibitor for 3 elimination half-lives, resume the TUKYSA dose that was taken prior to initiating the inhibitor [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] ."],"spl_product_data_elements":["TUKYSA tucatinib Tucatinib Tucatinib Copovidone K25-31 Crospovidone (120 .Mu.M) Sodium Chloride Potassium Chloride Sodium Bicarbonate Silicon Dioxide Magnesium Stearate Microcrystalline Cellulose 102 Polyvinyl Alcohol, Unspecified Titanium Dioxide Polyethylene Glycol, Unspecified Talc Ferric Oxide Yellow TUC;50 TUKYSA tucatinib Tucatinib Tucatinib Copovidone K25-31 Crospovidone (120 .Mu.M) Sodium Chloride Potassium Chloride Sodium Bicarbonate Silicon Dioxide Magnesium Stearate Microcrystalline Cellulose 102 Polyvinyl Alcohol, Unspecified Titanium Dioxide Polyethylene Glycol, Unspecified Talc Ferric Oxide Yellow TUC;150"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: • 50 mg: round, yellow, film-coated, debossed with “TUC” on one side and “50” on the other side. • 150 mg: oval-shaped, yellow, film-coated, debossed with “TUC” on one side and “150” on the other side. Tablets: 50 mg and 150 mg. ( 3 )"],"recent_major_changes_table":["
Indications and Usage (1.2)1/2023
Patient Selection (2.1)1/2023
Warnings and Precautions (5.1), (5.2)1/2023
"],"spl_patient_package_insert":["This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 01/2023 PATIENT INFORMATION TUKYSA ® (too-KYE-sah) (tucatinib) tablets Important information: If your healthcare provider prescribes TUKYSA in combination with capecitabine for your breast cancer, also read the Patient Information that comes with capecitabine. What is TUKYSA? TUKYSA is a prescription medicine used to treat adults with: • a type of breast cancer called human epidermal growth factor receptor-2 (HER2)-positive breast cancer. TUKYSA is used with the medicines trastuzumab and capecitabine, when your cancer has spread to other parts of the body such as the brain (metastatic), or cannot be removed by surgery, and you have received one or more anti-HER2 breast cancer treatments. • a type of colorectal cancer called RAS wild-type HER2-positive colorectal cancer. TUKYSA is used with the medicine trastuzumab, when your cancer has spread to other parts of the body (metastatic), or cannot be removed by surgery, and you have received treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and it did not work or is no longer working. It is not known if TUKYSA is safe and effective in children. Before taking TUKYSA, tell your healthcare provider about all of your medical conditions, including if you: • have liver problems. • are pregnant or plan to become pregnant. TUKYSA can harm your unborn baby. Females who are able to become pregnant: o Your healthcare provider will do a pregnancy test before you start treatment with TUKYSA. o You should use effective birth control (contraception) during treatment with TUKYSA and for 1 week after the last dose of TUKYSA. Talk with your healthcare provider about forms of birth control that you can use during this time. o Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TUKYSA. Males with female partner who are able to become pregnant should use effective birth control during treatment with TUKYSA and for 1 week after the last dose of TUKYSA. • are breastfeeding or plan to breastfeed. It is not known if TUKYSA passes into your breast milk. Do not breastfeed during treatment with TUKYSA and for 1 week after the last dose of TUKYSA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TUKYSA may affect the way your other medicines work, and other medicines may affect the way TUKYSA works. Know the medicines you take. Keep a list of all the medicines you take and show it to your healthcare provider and pharmacist every time you get a new medicine. How should I take TUKYSA? • Take TUKYSA exactly as your healthcare provider tells you. • TUKYSA is used with the medicine trastuzumab for colorectal cancer or with trastuzumab and capecitabine for breast cancer. Your healthcare provider will tell you the dose of trastuzumab and capecitabine you will take and how you will receive them. • Take TUKYSA 2 times a day, with or without a meal. • Take TUKYSA about 12 hours apart or at the same times every day. • Swallow TUKYSA tablets whole. Do not chew, crush, or split TUKYSA tablets before swallowing. Do not take TUKYSA tablets if they are broken, cracked, or damaged. • If you vomit or miss a dose of TUKYSA, take your next dose at your regular time. What are the possible side effects of TUKYSA? TUKYSA may cause serious side effects, including: • Diarrhea. Diarrhea is common with TUKYSA and can sometimes be severe. Tell your healthcare provider if you have a change in your bowel movements or severe diarrhea. Severe diarrhea can lead to loss of too much body fluids (dehydration), low blood pressure, kidney problems and death. Your healthcare provider may prescribe medicines to treat your diarrhea during treatment with TUKYSA. • Liver Problems. TUKYSA can cause severe liver problems. Your healthcare provider will do blood tests to check your liver function before and every 3 weeks during treatment with TUKYSA, or as needed. Tell your healthcare provider right away if you have any signs and symptoms of liver problems including: o itching o yellowing of your skin or eyes o dark or brown urine (tea-colored) o pain in the upper right side of your stomach-area (abdomen) o feel very tired o decreased appetite o bleeding or bruising more easily than normal The most common side effects of TUKYSA in combination with trastuzumab and capecitabine in adults with HER2-positive breast cancer include: • diarrhea • rash, redness, pain, swelling or blisters on the palms of your hands or soles of your feet • nausea • increased liver function blood tests • vomiting • mouth sores (stomatitis) • decreased appetite • low red blood cell counts (anemia) • rash The most common side effects of TUKYSA in combination with trastuzumab in adults with RAS wild-type HER2-positive colorectal cancer include: • diarrhea • tiredness • rash • nausea • stomach-area (abdomen) pain • infusion-related reactions • fever Your healthcare provider may change your dose of TUKYSA, temporarily stop, or permanently stop treatment with TUKYSA if you have certain side effects. TUKYSA may cause fertility problems in males and females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility. These are not all of the possible side effects of TUKYSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store TUKYSA? • Store TUKYSA at room temperature 68°F to 77°F (20ºC to 25ºC). • Keep TUKYSA in its original container. The TUKYSA bottle contains a desiccant packet to help keep your tablets dry (protect from moisture). Keep the desiccant in the bottle. • Tightly close the bottle of TUKYSA after you take your dose. • TUKYSA must be used within 3 months after opening the bottle. Throw away (discard) any unused tablets 3 months after opening the bottle. Keep TUKYSA and all medicines out of reach of children. General information about the safe and effective use of TUKYSA. Medicines are sometimes prescribed for conditions not listed in the Patient Information. Do not use TUKYSA for a condition for which it was not prescribed. Do not give TUKYSA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TUKYSA that is written for healthcare professionals. What are the ingredients in TUKYSA? Active ingredient: tucatinib Inactive ingredients: Tablet core: copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose. Tablet coating: yellow film coat: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, talc, and yellow iron oxide non-irradiated. Manufactured for: Seagen Inc., Bothell, WA 98021 TUKYSA is a registered trademark owned by Seagen Inc. ©2023 Seagen Inc. PPI-213411-v04 For more information, call 1-855-473-2436 (1-855-4SEAGEN) or go to www.TUKYSA.com ."],"clinical_pharmacology_table":["
Table 9: Tucatinib Cmax and AUC
Tumor TypeAUCss (ng*h/mL)Cmax,ss (ng/mL)Ctrough,ss (ng/mL)
mBC5620 (43)747 (45)288 (59)
mCRC3370 (49)405 (45)197 (63)
","
Table 10: Effect of Other Drugs on TUKYSA
Concomitant Drug (Dose)TUKYSA DoseRatio (90% CI) of Tucatinib Exposure With and Without Concomitant Drug
CmaxAUC
Strong CYP3A Inhibitor Itraconazole (200 mg BID)300 mg single dose1.3 (1.2, 1.4)1.3 (1.3, 1.4)
Strong CYP3A/Moderate 2C8 Inducer Rifampin (600 mg once daily)0.6 (0.5, 0.8)0.5 (0.4, 0.6)
Strong CYP2C8 Inhibitor Gemfibrozil (600 mg BID)1.6 (1.5, 1.8)3.0 (2.7, 3.5)
","
Table 11: Effect of TUKYSA on Other Drugs
Concomitant Drug (Dose)TUKYSA DoseRatio (90% CI) of Exposure Measures of Concomitant Drug with/without Tucatinib
CmaxAUC
CYP2C8 Substrate Repaglinide (0.5 mg single dose)300 mg twice daily1.7 (1.4, 2.1)1.7 (1.5, 1.9)
CYP3A Substrate Midazolam (2 mg single dose)3.0 (2.6, 3.4)5.7 (5.0, 6.5)
P-gp Substrate Digoxin (0.5 mg single dose)2.4 (1.9, 2.9)1.5 (1.3, 1.7)
MATE1/2-K substrateTucatinib reduced the renal clearance of metformin without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C. Metformin (850 mg single dose)1.1 (1.0, 1.2)1.4 (1.2, 1.5)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary TUKYSA is used in combination with trastuzumab and capecitabine. Refer to the Full Prescribing Information of trastuzumab and capecitabine for pregnancy information. Based on findings in animals and its mechanism of action, TUKYSA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available human data on TUKYSA use in pregnant women to inform a drug-associated risk. In animal reproduction studies, administration of tucatinib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal mortality, reduced fetal weight and fetal abnormalities at maternal exposures ≥ 1.3 times the human exposure (AUC) at the recommended dose (see Data ) . Advise pregnant women and females of reproductive potential of the potential risk to the fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Data Animal Data In pilot embryo-fetal development studies, pregnant rats and rabbits received oral doses of tucatinib up to 150 mg/kg/day during the period of organogenesis. In rats, oral administration of tucatinib resulted in maternal toxicity (body weight loss, reduced body weight gain, low food consumption) at doses ≥ 90 mg/kg/day. Fetal effects included reduced number of live fetuses, decreased fetal weight, and fetal abnormalities (increase in skeletal variations, incomplete ossification) at ≥ 90 mg/kg/day (approximately 3.5 times the human exposure at the recommended dose based on AUC). In rabbits, oral administration of tucatinib resulted in increased resorptions, decreased percentages of live fetuses, and skeletal, visceral, and external malformations in fetuses at doses ≥ 90 mg/kg/day (1.3 times the human exposure at the recommended dose based on AUC). Fetal abnormalities included domed head, brain dilation, incomplete ossification of frontal and parietal bones, and a hole in the parietal bone. 8.2 Lactation Risk Summary TUKYSA is used in combination with trastuzumab and capecitabine. Refer to the Full Prescribing Information of trastuzumab and capecitabine for lactation information. There are no data on the presence of tucatinib or its metabolites in human or animal milk or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with TUKYSA and for 1 week after the last dose. 8.3 Females and Males of Reproductive Potential TUKYSA can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . TUKYSA is used in combination with trastuzumab and capecitabine. Refer to the Full Prescribing Information of trastuzumab and capecitabine for contraception and infertility information. Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating treatment with TUKYSA. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose. Males Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose. Infertility Based on findings from animal studies, TUKYSA may impair male and female fertility [see Nonclinical Toxicology (13.1) ] . 8.4 Pediatric Use The safety and effectiveness of TUKYSA in pediatric patients have not been established. 8.5 Geriatric Use In HER2CLIMB, 82 patients who received TUKYSA were ≥ 65 years, of whom 8 patients were ≥ 75 years. The incidence of serious adverse reactions in those receiving TUKYSA was 34% in patients ≥ 65 years compared to 24% in patients <65 years. The most frequent serious adverse reactions in patients ≥65 years who received TUKYSA were diarrhea (9%), vomiting (6%), and nausea (5%). There were no observed overall differences in the effectiveness of TUKYSA in patients ≥ 65 years compared to younger patients. There were too few patients ≥75 years to assess differences in effectiveness or safety. In MOUNTAINEER, 12 patients were ≥65 years of age. There were too few patients ≥65 years to assess differences in effectiveness or safety. 8.6 Renal Impairment The use of TUKYSA in combination with capecitabine and trastuzumab is not recommended in patients with severe renal impairment (creatinine clearance [CLcr]: < 30 mL/min estimated by Cockcroft-Gault Equation), because capecitabine is contraindicated in patients with severe renal impairment. Refer to the Full Prescribing Information of capecitabine for additional information in severe renal impairment. No dose adjustment is recommended for patients with mild or moderate renal impairment (CLcr: 30 to 89 mL/min). 8.7 Hepatic Impairment Tucatinib exposure is increased in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of TUKYSA for patients with severe (Child-Pugh C) hepatic impairment [see Dosage and Administration (2.3) , Clinical Pharmacology (12.3) ] . No dose adjustment for TUKYSA is required for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment."],"dosage_and_administration_table":["
Table 1: Recommended TUKYSA Dose Reductions for Adverse Reactions
Dose ReductionRecommended TUKYSA Dosage
First250 mg orally twice daily
Second200 mg orally twice daily
Third150 mg orally twice daily
","
Table 2: Recommended TUKYSA Dosage Modifications for Adverse Reactions
Adverse ReactionGrades based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03SeverityTUKYSA Dosage Modification
Diarrhea [see Warnings and Precautions (5.1)]Grade 3 without anti-diarrheal treatmentInitiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose level.
Grade 3 with anti-diarrheal treatmentInitiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level.
Grade 4Permanently discontinue TUKYSA.
HepatotoxicityAbbreviations: ULN = upper limit of normal; ALT = alanine aminotransferase; AST = aspartate aminotransferase[see Warnings and Precautions (5.2)]Grade 2 bilirubin (>1.5 to 3 × ULN)Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose level.
Grade 3 ALT or AST (> 5 to 20 × ULN) OR Grade 3 bilirubin (> 3 to 10 × ULN)Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level.
Grade 4 ALT or AST (> 20 × ULN) OR Grade 4 bilirubin (> 10 × ULN)Permanently discontinue TUKYSA.
ALT or AST > 3 × ULN AND Bilirubin > 2 × ULNPermanently discontinue TUKYSA.
Other adverse reactions [see Adverse Reactions (6.1)]Grade 3Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level.
Grade 4Permanently discontinue TUKYSA.
"],"spl_patient_package_insert_table":["a type of breast cancer called human epidermal growth factor receptor-2 (HER2)-positive breast cancer. TUKYSA is used with the medicines trastuzumab and capecitabine, when your cancer has spread to other parts of the body such as the brain (metastatic), or cannot be removed by surgery, and you have received one or more anti-HER2 breast cancer treatments.a type of colorectal cancer called RAS wild-type HER2-positive colorectal cancer. TUKYSA is used with the medicine trastuzumab, when your cancer has spread to other parts of the body (metastatic), or cannot be removed by surgery, and you have received treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and it did not work or is no longer working.It is not known if TUKYSA is safe and effective in children.have liver problems.are pregnant or plan to become pregnant. TUKYSA can harm your unborn baby. Females who are able to become pregnant:Your healthcare provider will do a pregnancy test before you start treatment with TUKYSA.You should use effective birth control (contraception) during treatment with TUKYSA and for 1 week after the last dose of TUKYSA. Talk with your healthcare provider about forms of birth control that you can use during this time.Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TUKYSA.Males with female partner who are able to become pregnant should use effective birth control during treatment with TUKYSA and for 1 week after the last dose of TUKYSA.are breastfeeding or plan to breastfeed. It is not known if TUKYSA passes into your breast milk. Do not breastfeed during treatment with TUKYSA and for 1 week after the last dose of TUKYSA.Take TUKYSA exactly as your healthcare provider tells you.TUKYSA is used with the medicine trastuzumab for colorectal cancer or with trastuzumab and capecitabine for breast cancer. Your healthcare provider will tell you the dose of trastuzumab and capecitabine you will take and how you will receive them.Take TUKYSA 2 times a day, with or without a meal.Take TUKYSA about 12 hours apart or at the same times every day.Swallow TUKYSA tablets whole. Do not chew, crush, or split TUKYSA tablets before swallowing. Do not take TUKYSA tablets if they are broken, cracked, or damaged.If you vomit or miss a dose of TUKYSA, take your next dose at your regular time.Diarrhea. Diarrhea is common with TUKYSA and can sometimes be severe. Tell your healthcare provider if you have a change in your bowel movements or severe diarrhea. Severe diarrhea can lead to loss of too much body fluids (dehydration), low blood pressure, kidney problems and death. Your healthcare provider may prescribe medicines to treat your diarrhea during treatment with TUKYSA.Liver Problems. TUKYSA can cause severe liver problems. Your healthcare provider will do blood tests to check your liver function before and every 3 weeks during treatment with TUKYSA, or as needed. Tell your healthcare provider right away if you have any signs and symptoms of liver problems including:itchingyellowing of your skin or eyesdark or brown urine (tea-colored)pain in the upper right side of your stomach-area (abdomen)feel very tireddecreased appetitebleeding or bruising more easily than normaldiarrhearash, redness, pain, swelling or blisters on the palms of your hands or soles of your feetnauseaincreased liver function blood testsvomitingmouth sores (stomatitis)decreased appetitelow red blood cell counts (anemia)rashdiarrheatirednessrashnauseastomach-area (abdomen) paininfusion-related reactionsfeverStore TUKYSA at room temperature 68°F to 77°F (20ºC to 25ºC).Keep TUKYSA in its original container. The TUKYSA bottle contains a desiccant packet to help keep your tablets dry (protect from moisture). Keep the desiccant in the bottle.Tightly close the bottle of TUKYSA after you take your dose.TUKYSA must be used within 3 months after opening the bottle. Throw away (discard) any unused tablets 3 months after opening the bottle.
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 01/2023
PATIENT INFORMATION TUKYSA® (too-KYE-sah) (tucatinib) tablets
Important information: If your healthcare provider prescribes TUKYSA in combination with capecitabine for your breast cancer, also read the Patient Information that comes with capecitabine.
What is TUKYSA? TUKYSA is a prescription medicine used to treat adults with:
••
Before taking TUKYSA, tell your healthcare provider about all of your medical conditions, including if you:
••ooo •
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TUKYSA may affect the way your other medicines work, and other medicines may affect the way TUKYSA works.Know the medicines you take. Keep a list of all the medicines you take and show it to your healthcare provider and pharmacist every time you get a new medicine.
How should I take TUKYSA?
••••••
What are the possible side effects of TUKYSA? TUKYSA may cause serious side effects, including:
••
oooo
ooo
The most common side effects of TUKYSA in combination with trastuzumab and capecitabine in adults with HER2-positive breast cancer include:
•••••
••••
The most common side effects of TUKYSA in combination with trastuzumab in adults with RAS wild-type HER2-positive colorectal cancer include:
•••
••••
Your healthcare provider may change your dose of TUKYSA, temporarily stop, or permanently stop treatment with TUKYSA if you have certain side effects. TUKYSA may cause fertility problems in males and females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility. These are not all of the possible side effects of TUKYSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store TUKYSA?
••••
Keep TUKYSA and all medicines out of reach of children.
General information about the safe and effective use of TUKYSA. Medicines are sometimes prescribed for conditions not listed in the Patient Information. Do not use TUKYSA for a condition for which it was not prescribed. Do not give TUKYSA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TUKYSA that is written for healthcare professionals.
What are the ingredients in TUKYSA? Active ingredient: tucatinib Inactive ingredients: Tablet core: copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose.Tablet coating: yellow film coat: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, talc, and yellow iron oxide non-irradiated. Manufactured for: Seagen Inc., Bothell, WA 98021 TUKYSA is a registered trademark owned by Seagen Inc. ©2023 Seagen Inc. PPI-213411-v04 For more information, call 1-855-473-2436 (1-855-4SEAGEN) or go to www.TUKYSA.com.
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 51144- 001 -60 Rx Only TUKYSA ® (tucatinib) tablets 50 mg* Attention: Dispense and store Tukysa in original container to protect from moisture. Seagen ® 60 Tablets * Each tablet contains 50 mg tucatinib. Recommended Dosage: See prescribing information Store at controlled room temperature, 20°C to 25°C (68° to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. KEEP OUT OF REACH OF CHILDREN Discard unused tablets 3 months after opening. Mfg for: Seagen Inc. Bothell, WA 98021 USA TUKYSA and its logo are US registered trademarks of Seagen Inc. ©2023 Seagen Inc. All rights reserved. Printed in USA 00000000 GTIN 00351144001607 LOT: 123456 EXP: MMMYYYY SN: 12345678901234 NDC 51144- 002 -60 Rx Only TUKYSA ® (tucatinib) tablets 150 mg* Attention: Dispense and store Tukysa in original container to protect from moisture. Seagen ® 60 Tablets * Each tablet contains 150 mg tucatinib. Recommended Dosage: See prescribing information Store at controlled room temperature, 20°C to 25°C (68° to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. KEEP OUT OF REACH OF CHILDREN Discard unused tablets 3 months after opening. Mfg for: Seagen Inc. Bothell, WA 98021 USA TUKYSA and its logo are US registered trademarks of Seagen Inc. ©2023 Seagen Inc. All rights reserved. Printed in USA 00000000 GTIN 00351144002604 LOT: 123456 EXP: MMMYYYY SN: 12345678901234 NDC 51144- 002 -12 Rx Only TUKYSA ® (tucatinib) tablets 150 mg* Attention: Dispense and store Tukysa in original container to protect from moisture. SeaGen ® 120 Tablets * Each tablet contains 150 mg tucatinib. Recommended Dosage: See prescribing information Store at controlled room temperature, 20°C to 25°C (68° to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. KEEP OUT OF REACH OF CHILDREN Discard unused tablets 3 months after opening. Mfg for: Seagen Inc. Bothell, WA 98021 USA TUKYSA and its logo are US registered trademarks of Seagen Inc. ©2021 Seagen Inc. All rights reserved. Printed in USA 1204-02 GTIN 00351144002604 LOT: 123456 EXP: MMMYYYY SN: 12345678901234 50 mg Label 150 mg Label 60 count 150 mg Label 120 count"],"drug_and_or_laboratory_test_interactions":["7.1 Effects of Other Drugs on TUKYSA Table 7 summarizes the effect of other drugs on TUKYSA. Table 7: Drug Interactions that Affect TUKYSA Strong CYP3A Inducers or Moderate CYP2C8 Inducers Clinical Impact Concomitant use of TUKYSA with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib plasma concentrations [see Clinical Pharmacology (12.3) ] , which may reduce TUKYSA activity. Management Avoid concomitant use of TUKYSA with a strong CYP3A inducer or a moderate CYP2C8 inducer. Strong or Moderate CYP2C8 Inhibitors Clinical Impact Concomitant use of TUKYSA with a strong CYP2C8 inhibitor increased tucatinib plasma concentrations [see Clinical Pharmacology (12.3) ] , which may increase the risk of TUKYSA toxicity. Management Avoid concomitant use of TUKYSA with a strong CYP2C8 inhibitor. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.","7.2 Effects of TUKYSA on Other Drugs Table 8 summarizes the effect of TUKYSA on other drugs. Table 8: TUKYSA Drug Interactions that Affect Other Drugs CYP3A Substrates Clinical Impact Concomitant use of TUKYSA with a CYP3A substrate increased the plasma concentrations of CYP3A substrate [see Clinical Pharmacology (12.3) ] , which may increase the toxicity associated with a CYP3A substrate. Management Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling. P-glycoprotein (P-gp) Substrates Clinical Impact Concomitant use of TUKYSA with a P-gp substrate increased the plasma concentrations of P-gp substrate [see Clinical Pharmacology (12.3) ] , which may increase the toxicity associated with a P-gp substrate. Management Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities."],"drug_and_or_laboratory_test_interactions_table":["
Table 7: Drug Interactions that Affect TUKYSA
Strong CYP3A Inducers or Moderate CYP2C8 Inducers
Clinical ImpactConcomitant use of TUKYSA with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib plasma concentrations [see Clinical Pharmacology (12.3)], which may reduce TUKYSA activity.
ManagementAvoid concomitant use of TUKYSA with a strong CYP3A inducer or a moderate CYP2C8 inducer.
Strong or Moderate CYP2C8 Inhibitors
Clinical ImpactConcomitant use of TUKYSA with a strong CYP2C8 inhibitor increased tucatinib plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of TUKYSA toxicity.
ManagementAvoid concomitant use of TUKYSA with a strong CYP2C8 inhibitor. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
","
Table 8: TUKYSA Drug Interactions that Affect Other Drugs
CYP3A Substrates
Clinical ImpactConcomitant use of TUKYSA with a CYP3A substrate increased the plasma concentrations of CYP3A substrate [see Clinical Pharmacology (12.3)], which may increase the toxicity associated with a CYP3A substrate.
ManagementAvoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling.
P-glycoprotein (P-gp) Substrates
Clinical ImpactConcomitant use of TUKYSA with a P-gp substrate increased the plasma concentrations of P-gp substrate [see Clinical Pharmacology (12.3)], which may increase the toxicity associated with a P-gp substrate.
ManagementConsider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.
"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with tucatinib. Tucatinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay. Tucatinib was not clastogenic in either an in vitro chromosome aberration assay or an in vivo mouse bone marrow micronucleus assay. Fertility studies in animals have not been conducted. In repeat-dose toxicity studies up to 13 weeks duration, decreased corpora lutea/corpus luteum cyst, increased interstitial cells of the ovary, atrophy of the uterus, and mucification of the vagina were observed in female rats at doses ≥ 6 mg/kg/day (approximately 0.1 times the human exposure at the recommended dose based on AUC). Atrophy and edema of the testes and oligospermia/germ cell debris in the epididymides were observed in male rats at ≥ 120 mg/kg/day (approximately 13 times the human exposure at the recommended dose based on AUC)."]},"tags":[{"label":"Kinase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"ERBB2/ERBB3","category":"target"},{"label":"ERBB2","category":"gene"},{"label":"ERBB3","category":"gene"},{"label":"MYH14","category":"gene"},{"label":"L01EH03","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","category":"indication"},{"label":"Seagen","category":"company"},{"label":"Approved 2020s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protein Kinase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1650 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"883 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"881 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"499 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"455 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"433 reports"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"382 reports"},{"date":"","signal":"PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME","source":"FDA FAERS","actionTaken":"373 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"342 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"338 reports"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"81%","severity":"serious","_validated":true},{"effect":"Palmar-plantar erythrodysesthesia syndrome","drugRate":"63%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"58%","severity":"serious","_validated":true},{"effect":"Vomiting","drugRate":"36%","severity":"serious","_validated":true},{"effect":"Stomatitis","drugRate":"32%","severity":"serious","_validated":true},{"effect":"Hepatotoxicity","drugRate":"42%","severity":"serious","_validated":true},{"effect":"Decreased appetite","drugRate":"25%","severity":"serious","_validated":true},{"effect":"Anemia","drugRate":"21%","severity":"serious","_validated":true},{"effect":"Rash","drugRate":"20%","severity":"serious","_validated":true},{"effect":"Abdominal pain","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Headache","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Fatigue","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Hepatobiliary disorders","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Metabolism and nutrition disorders","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Blood and lymphatic system disorders","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Musculoskeletal and connective tissue disorders","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Investigations","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Nervous System Disorders","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Respiratory, thoracic and mediastinal disorders","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Creatinine increased","drugRate":"14%","severity":"mild","_validated":true},{"effect":"Weight decreased","drugRate":"13%","severity":"mild","_validated":true},{"effect":"Peripheral neuropathy","drugRate":"13%","severity":"mild","_validated":true},{"effect":"Epistaxis","drugRate":"12%","severity":"mild","_validated":true},{"effect":"Decreased phosphate","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Increased bilirubin","drugRate":"10%","severity":"mild","_validated":true}],"specialPopulations":{"Lactation":"There are no data on the presence of tucatinib or its metabolites in human or animal milk or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed child, advise women not to breastfeed during treatment with TUKYSA and for at least week","Pregnancy":"Based on findings in animals and its mechanism of action, TUKYSA can cause fetal harm when administered to pregnant woman. There are no available human data on TUKYSA use in pregnant women to inform drug-associated risk. In animal reproduction studies, administration of tucatinib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal mortality, reduced fetal weight and fetal abnormalities at maternal exposures >= 1.3 times the human exposure (AUC) at the recommended dose. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.","Geriatric use":"In HER2CLIMB, 82 patients who received TUKYSA were >= 65 years, of whom patients were >= 75 years. The incidence of serious adverse reactions in those receiving TUKYSA was 34% in patients >= 65 years compared to 24% in patients <65 years. The most frequent serious adverse reactions in patients who received TUKYSA and >= 65 years were diarrhea (9%), vomiting (6%), and nausea (5%). There were no observed overall differences in the effectiveness of TUKYSA in patients >= 65 years","Paediatric use":"The safety and effectiveness of TUKYSA in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Seagen","patents":[{"applNo":"N213411","source":"FDA Orange Book","status":"Active","expires":"Mar 25, 2033","useCode":"U-2788","territory":"US","drugProduct":false,"patentNumber":"11504370","drugSubstance":false},{"applNo":"N213411","source":"FDA Orange Book","status":"Active","expires":"Apr 27, 2038","useCode":"U-3783","territory":"US","drugProduct":false,"patentNumber":"11666572","drugSubstance":false},{"applNo":"N213411","source":"FDA Orange Book","status":"Active","expires":"Apr 27, 2038","useCode":"U-3783","territory":"US","drugProduct":false,"patentNumber":"12048698","drugSubstance":false},{"applNo":"N213411","source":"FDA Orange Book","status":"Active","expires":"Oct 12, 2032","useCode":"U-2788","territory":"US","drugProduct":true,"patentNumber":"9457093","drugSubstance":false},{"applNo":"N213411","source":"FDA Orange Book","status":"Active","expires":"May 9, 2027","useCode":"U-2788","territory":"US","drugProduct":true,"patentNumber":"9693989","drugSubstance":false},{"applNo":"N213411","source":"FDA Orange Book","status":"Active","expires":"Apr 27, 2038","useCode":"U-3783","territory":"US","drugProduct":false,"patentNumber":"11207324","drugSubstance":false},{"applNo":"N213411","source":"FDA Orange Book","status":"Active","expires":"Jan 14, 2031","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8648087","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tucatinib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:42:34.361210+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:42:32.417181+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Tucatinib","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:42:41.243397+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:42:39.640780+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:42:34.430166+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:42:31.055430+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tucatinib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:42:40.028000+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:30.533624+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:30.533656+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:30.533661+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:42:41.755578+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Receptor protein-tyrosine kinase erbB-2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:42:41.243305+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989868/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:42:40.805886+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA213411","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:30.533663+00:00"}},"allNames":"tukysa","offLabel":[],"synonyms":["tucatinib","tukysa","ARRY-380","ONT-380"],"timeline":[{"date":"2020-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from SEATTLE GENETICS to Seagen"},{"date":"2020-04-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Seattle Genetics)"},{"date":"2021-02-11","type":"positive","source":"DrugCentral","milestone":"EMA approval (Seagen B.V)"},{"date":"2026-01-19","type":"negative","source":"FDA Orange Book","milestone":"I-906 exclusivity expires"},{"date":"2027-04-17","type":"negative","source":"FDA Orange Book","milestone":"ODE-309 exclusivity expires"},{"date":"2030-01-19","type":"negative","source":"FDA Orange Book","milestone":"ODE-422 exclusivity expires"},{"date":"2031-01-14","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8648087 expires"}],"aiSummary":"Tukysa (tucatinib) is a small molecule kinase inhibitor developed by SEATTLE GENETICS and currently owned by Seagen. It targets the ERBB2/ERBB3 receptors, which are involved in the growth and spread of cancer cells. Tukysa is FDA-approved for the treatment of metastatic human epidermal growth factor 2 positive carcinoma of the breast. It is a patented medication with no generic manufacturers available. Key safety considerations include its potential to cause liver damage and interactions with other medications.","brandName":"Tukysa","ecosystem":[{"indication":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","otherDrugs":[{"name":"margetuximab","slug":"margetuximab","company":"Macrogenics Inc"},{"name":"trastuzumab deruxtecan","slug":"trastuzumab-deruxtecan","company":"Daiichi Sankyo"}],"globalPrevalence":null}],"mechanism":{"target":"ERBB2/ERBB3","novelty":"Follow-on","targets":[{"gene":"ERBB2","source":"DrugCentral","target":"ERBB2/ERBB3","protein":"Receptor tyrosine-protein kinase erbB-2"},{"gene":"ERBB3","source":"DrugCentral","target":"ERBB2/ERBB3","protein":"Receptor tyrosine-protein kinase erbB-3"},{"gene":"MYH14","source":"DrugCentral","target":"Myosin-14","protein":"Myosin-14"},{"gene":"ERBB4","source":"DrugCentral","target":"Receptor tyrosine-protein kinase erbB-4","protein":"Receptor tyrosine-protein kinase erbB-4"},{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"},{"gene":"RIPK3","source":"DrugCentral","target":"Receptor-interacting serine/threonine-protein kinase 3","protein":"Receptor-interacting serine/threonine-protein kinase 3"},{"gene":"NQO2","source":"DrugCentral","target":"Ribosyldihydronicotinamide dehydrogenase [quinone]","protein":"Ribosyldihydronicotinamide dehydrogenase [quinone]"},{"gene":"FECH","source":"DrugCentral","target":"Ferrochelatase, mitochondrial","protein":"Ferrochelatase, mitochondrial"}],"moaClass":"Cytochrome P450 2C8 Inhibitors","modality":"Small Molecule","drugClass":"Kinase Inhibitor [EPC]","explanation":"Tucatinib is tyrosine kinase inhibitor of HER2. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo, tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone.","oneSentence":"Tukysa works by blocking the ERBB2/ERBB3 receptors, which are involved in the growth and spread of cancer cells.","technicalDetail":"Tukysa is a small molecule inhibitor of the ERBB2/ERBB3 tyrosine kinases, which are involved in the activation of downstream signaling pathways that promote cell proliferation and survival.","_target_confidence":0.5},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Tucatinib","title":"Tucatinib","extract":"Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and licensed to Cascadian Therapeutics.","wiki_history":"== History ==\nIn April 2020, the U.S. Food and Drug Administration (FDA) approved tucatinib in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adults with advanced forms of HER2-positive breast cancer that can't be removed with surgery, or has spread to other parts of the body, including the brain, and who have received one or more prior treatments.\n\nThe FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA, Singapore) and Swissmedic (SMC, Switzerland) on the review. The FDA granted approval of Tukysa to Seattle Genetics, Inc.","wiki_society_and_culture":"== Society and culture ==\n=== Economics ===\nTucatinib was denied entry into the Australian Pharmaceutical Benefits Scheme in March 2021, as \"the incremental cost effectiveness ratio was unacceptably high at the proposed price\".\n\n=== Legal status ===\nTucatinib was approved for medical use in the United States in April 2020.\n\nTucatinib was approved for medical use in Australia in August 2020. The applicant for this medicinal product is Seagen B.V. [https://emergencydrug.com/shop/tucaxen-tucatinib-150mg Tucaxen] is one of the Tucanitib generic brands, manufactuctured by Everest Pharmaceuticals Ltd, a Bangladeshi well-known pharma company."},"commercial":{"launchDate":"2020","revenueYear":2025,"_launchSource":"DrugCentral (FDA 2020-04-17, SEATTLE GENETICS)","annualRevenue":463,"revenueSource":"Verified: Pfizer 8-K FY2025","revenueCurrency":"USD","revenueConfidence":"verified","revenueExtractedAt":"2026-04-01T11:46:20.997448","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5389","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=tucatinib","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tucatinib","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Tucatinib","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:10:20.800454","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:42:44.572021+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"lapatinib","drugSlug":"lapatinib","fdaApproval":"2007-03-13","patentExpiry":"Sep 18, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"neratinib","drugSlug":"neratinib","fdaApproval":"2017-07-17","patentExpiry":"Oct 15, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"I-906","date":"Jan 19, 2026"},{"code":"ODE-309","date":"Apr 17, 2027"},{"code":"ODE-422","date":"Jan 19, 2030"},{"code":"I-906","date":"Jan 19, 2026"},{"code":"ODE-309","date":"Apr 17, 2027"},{"code":"ODE-422","date":"Jan 19, 2030"}],"genericName":"tucatinib","indications":{"approved":[{"name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","source":"DrugCentral","snomedId":459391000124109,"regulator":"FDA","eligibility":"adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting"}],"offLabel":[],"pipeline":[]},"currentOwner":"Seagen","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"lapatinib","brandName":"lapatinib","genericName":"lapatinib","approvalYear":"2007","relationship":"same-class"},{"drugId":"neratinib","brandName":"neratinib","genericName":"neratinib","approvalYear":"2017","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":["Lymphoma, Non-Hodgkin","Multiple Myeloma","Advanced Solid Tumors"],"enrollment":720,"completionDate":"2027-01-31"},{"nctId":"NCT07494448","phase":"PHASE1,PHASE2","title":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07-01","conditions":["HER 2 Positive Advanced Breast Cancer","Breast Cancer"],"enrollment":24,"completionDate":"2028-05-31"},{"nctId":"NCT04539938","phase":"PHASE2","title":"A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-12-01","conditions":["HER2 Positive Breast Cancer"],"enrollment":70,"completionDate":"2025-03-07"},{"nctId":"NCT05748834","phase":"PHASE2","title":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-07-24","conditions":["Breast Cancer"],"enrollment":36,"completionDate":"2027-11"},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":["Lymphoma, Non-Hodgkin","Multiple Myeloma","Advanced Solid Tumors"],"enrollment":4200,"completionDate":"2028-12-31"},{"nctId":"NCT05323955","phase":"PHASE2","title":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carey Anders, M.D.","startDate":"2023-03-23","conditions":["Brain Metastases","Human Epidermal Growth Factor 2 Positive Carcinoma of Breast","Advanced Breast Cancer"],"enrollment":48,"completionDate":"2026-07"},{"nctId":"NCT06157892","phase":"PHASE2","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2024-05-20","conditions":["Breast Neoplasms","Gastroesophageal Junction Adenocarcinoma","HER2 Low Breast Neoplasms","HER2 Positive Breast Neoplasms","Stomach Neoplasms","Triple Negative Breast Neoplasms","Metastatic Breast Cancer","Metastatic Gastric Cancer","Advanced Breast Cancer","Advanced Gastric Cancer"],"enrollment":172,"completionDate":"2029-07-28"},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":["HER2 Positive Breast Cancer"],"enrollment":654,"completionDate":"2027-09-28"},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":["Colorectal Neoplasms"],"enrollment":400,"completionDate":"2029-07-27"},{"nctId":"NCT05230810","phase":"PHASE1,PHASE2","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Criterium, Inc.","startDate":"2022-08-25","conditions":["HER2-positive Metastatic Breast Cancer"],"enrollment":40,"completionDate":"2026-06-30"},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":["Breast Neoplasms","Breast Cancer","Breast Tumors","Angiosarcoma","TNBC - Triple-Negative Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","Hormone Receptor Positive Tumor","Hormone Receptor Negative Tumor","Early-stage Breast Cancer","Locally Advanced Breast Cancer"],"enrollment":5000,"completionDate":"2031-12"},{"nctId":"NCT05382364","phase":"PHASE1","title":"Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-06-29","conditions":["Metastatic HER2+ Advanced Breast Cancer","Breast Neoplasms","Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)","Colorectal Cancer"],"enrollment":25,"completionDate":"2026-12-31"},{"nctId":"NCT07413939","phase":"PHASE2,PHASE3","title":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-04-30","conditions":["HER2-positive Breast Cancer"],"enrollment":650,"completionDate":"2032-08-28"},{"nctId":"NCT06983691","phase":"NA","title":"Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-04","conditions":["HER2+ Metastatic Breast Cancer (MBC)"],"enrollment":26,"completionDate":"2026-12"},{"nctId":"NCT05672524","phase":"PHASE2","title":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-12-30","conditions":["Adenocarcinoma of the Rectum","Locally Advanced Rectal Adenocarcinoma","Rectal Adenocarcinoma","HER2 Positive Rectal Adenocarcinoma","Rectal Cancer"],"enrollment":37,"completionDate":"2030-07-31"},{"nctId":"NCT07318389","phase":"EARLY_PHASE1","title":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-10","conditions":["Dynamic Tumor Resistance","Metastatic Colorectal Cancer"],"enrollment":100,"completionDate":"2029-11-14"},{"nctId":"NCT04430738","phase":"PHASE2","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-09-15","conditions":["Colorectal Carcinoma","Gastric Adenocarcinoma","GEJ Adenocarcinoma","Esophageal Adenocarcinoma","Cholangiocarcinoma","Gallbladder Carcinoma"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT07193394","phase":"PHASE2","title":"Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2026-01-31","conditions":["Metastatic Breast Cancer ( HER2 Negative)","Unresectable Breast Cancer"],"enrollment":20,"completionDate":"2029-06-08"},{"nctId":"NCT06016387","phase":"PHASE2","title":"Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-11-25","conditions":["HER2-positive Breast Cancer","LMD"],"enrollment":30,"completionDate":"2028-10-05"},{"nctId":"NCT06686394","phase":"PHASE1,PHASE2","title":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-02-26","conditions":["Breast Neoplasms","Breast Cancer"],"enrollment":81,"completionDate":"2030-04-18"},{"nctId":"NCT05892068","phase":"PHASE2","title":"A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-09","conditions":["Metastatic Breast Cancer"],"enrollment":9,"completionDate":"2028-05-09"},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":["Stage II Colon Cancer","Stage III Colon Cancer","HER2-positive Colon Cancer","RAS Wild-type Colon Cancer"],"enrollment":477,"completionDate":"2029-12"},{"nctId":"NCT06828588","phase":"EARLY_PHASE1","title":"Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-02","conditions":["Locally Advanced Cancer","Metastatic Cancer","HER2","HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma","HER 2 Low-expressing Breast Cancer"],"enrollment":30,"completionDate":"2029-12"},{"nctId":"NCT05673928","phase":"PHASE2","title":"A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-05-16","conditions":["Metastatic Solid Tumor","Brain Metastases"],"enrollment":30,"completionDate":"2029-03-01"},{"nctId":"NCT05458674","phase":"PHASE2","title":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","status":"RECRUITING","sponsor":"Criterium, Inc.","startDate":"2024-01-30","conditions":["Breast Cancer","Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer"],"enrollment":30,"completionDate":"2027-08-01"},{"nctId":"NCT06961331","phase":"","title":"Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-05-07","conditions":["Metastatic HER2+ Advanced Breast Cancer"],"enrollment":86,"completionDate":"2025-09-25"},{"nctId":"NCT04721977","phase":"PHASE2","title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-04-08","conditions":["Breast Cancer"],"enrollment":66,"completionDate":"2026-06-30"},{"nctId":"NCT05553522","phase":"PHASE1","title":"Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Baptist Health South Florida","startDate":"2024-01-29","conditions":["Brain Metastases","HER2-positive Breast Cancer"],"enrollment":1,"completionDate":"2025-12-17"},{"nctId":"NCT04579380","phase":"PHASE2","title":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2021-01-11","conditions":["Uterine Neoplasms","Uterine Cervical Neoplasms","Biliary Tract Neoplasms","Urologic Neoplasms","Carcinoma, Non-Small-Cell Lung","HER2 Mutations Breast Neoplasms"],"enrollment":217,"completionDate":"2026-04-30"},{"nctId":"NCT05583110","phase":"PHASE2","title":"Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2023-03-08","conditions":["HER2-positive Metastatic Breast Cancer","Locally Advanced HER2 Positive Breast Carcinoma"],"enrollment":13,"completionDate":"2025-05-30"},{"nctId":"NCT03975647","phase":"PHASE3","title":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2019-10-02","conditions":["HER2-positive Breast Cancer"],"enrollment":466,"completionDate":"2029-03-10"},{"nctId":"NCT04538742","phase":"PHASE1,PHASE2","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-28","conditions":["Metastatic Breast Cancer"],"enrollment":245,"completionDate":"2030-01-31"},{"nctId":"NCT05253911","phase":"","title":"Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2022-05-21","conditions":["HER2-positive Breast Cancer"],"enrollment":49,"completionDate":"2025-06-30"},{"nctId":"NCT05800275","phase":"PHASE2","title":"Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-12-18","conditions":["Leptomeningeal Metastasis","Leptomeningeal Disease","HER2-positive Metastatic Breast Cancer"],"enrollment":30,"completionDate":"2027-06"},{"nctId":"NCT05041842","phase":"PHASE2","title":"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2021-12-17","conditions":["Metastatic Breast Cancer With a Isolated Brain Progression"],"enrollment":53,"completionDate":"2026-04-30"},{"nctId":"NCT04457596","phase":"PHASE3","title":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-03-02","conditions":["Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","HER2 Positive Breast Carcinoma","Invasive Breast Carcinoma","Multifocal Breast Carcinoma","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Synchronous Bilateral Breast Carcinoma"],"enrollment":1056,"completionDate":"2035-05-31"},{"nctId":"NCT06239467","phase":"PHASE1","title":"First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer","status":"RECRUITING","sponsor":"OnKure, Inc.","startDate":"2024-02-26","conditions":["Advanced Cancer","Breast Cancer","Advanced Solid Tumors","PI3K Gene Mutation"],"enrollment":200,"completionDate":"2027-08-01"},{"nctId":"NCT03501979","phase":"PHASE2","title":"Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2019-02-20","conditions":["Metastatic Breast Cancer","Leptomeningeal Disease"],"enrollment":17,"completionDate":"2021-06-22"},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":["Breast Cancer Female","Breast Cancer","Breast Cancer Metastatic","Estrogen Receptor-positive Breast Cancer","HER2-positive Breast Cancer","Stage IV Breast Cancer"],"enrollment":72,"completionDate":"2033-03-30"},{"nctId":"NCT04220203","phase":"","title":"Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer","status":"APPROVED_FOR_MARKETING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"","conditions":["HER2-positive Breast Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT04789096","phase":"PHASE2","title":"Tucatinib Together With Pembrolizumab and Trastuzumab","status":"TERMINATED","sponsor":"Breast Cancer Trials, Australia and New Zealand","startDate":"2023-03-07","conditions":["Breast Cancer","HER2-positive Breast Cancer"],"enrollment":31,"completionDate":"2025-06-04"},{"nctId":"NCT05319873","phase":"PHASE1,PHASE2","title":"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-04-07","conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Invasive Breast Carcinoma","Locally Advanced HER2-Positive Breast Carcinoma","Metastatic HER2-Positive Breast Carcinoma","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8"],"enrollment":18,"completionDate":"2027-04-01"},{"nctId":"NCT05868226","phase":"PHASE1","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2023-02-15","conditions":["HER2-positive Breast Cancer","Metastatic Cancer","Metastatic Breast Cancer","Metastatic","HER2-positive Metastatic Breast Cancer","HER2 Mutation-Related Tumors","HER-2 Protein Overexpression","HER2-negative Breast Cancer","Triple Negative Breast Cancer","HR Positive","Hormone Receptor-positive Breast Cancer","Estrogen Receptor Positive Tumor","Progesterone Receptor-positive Breast Cancer","Hormone Receptor Negative Breast Carcinoma","Solid Tumor","Solid Tumor, Adult","Solid Carcinoma","HER2 Low Breast Cancer","HER2 Low Breast Carcinoma","ER Positive Breast Cancer","PR-positive Breast Cancer"],"enrollment":124,"completionDate":"2029-12-30"},{"nctId":"NCT05955170","phase":"PHASE2","title":"Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2023-12-19","conditions":["HER2-positive Breast Cancer"],"enrollment":66,"completionDate":"2028-12-19"},{"nctId":"NCT06839547","phase":"","title":"A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-01","conditions":["Advanced Breast Cancer Brain Metastasis"],"enrollment":100,"completionDate":"2028-09-10"},{"nctId":"NCT04499924","phase":"PHASE2,PHASE3","title":"Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2021-03-22","conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma"],"enrollment":17,"completionDate":"2024-04-17"},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":["Advanced Unresectable or Metastatic Solid Malignancy"],"enrollment":252,"completionDate":"2024-02-27"},{"nctId":"NCT02892123","phase":"PHASE1","title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-09-30","conditions":["HER2-expressing Cancers"],"enrollment":279,"completionDate":"2024-10-31"},{"nctId":"NCT03043313","phase":"PHASE2","title":"Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2017-06-23","conditions":["Metastatic Colorectal Adenocarcinoma"],"enrollment":117,"completionDate":"2023-11-02"},{"nctId":"NCT05356897","phase":"PHASE2","title":"Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study","status":"WITHDRAWN","sponsor":"Academic and Community Cancer Research United","startDate":"2023-10-31","conditions":["Metastatic Colon Adenocarcinoma","Metastatic Colorectal Adenocarcinoma","Metastatic Rectal Adenocarcinoma","Stage IV Colon Cancer AJCC V8","Stage IV Colorectal Cancer AJCC V8","Stage IV Rectal Cancer AJCC V8"],"enrollment":0,"completionDate":"2024-09-17"},{"nctId":"NCT06162559","phase":"PHASE1","title":"Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2023-12-18","conditions":["Breast Cancer"],"enrollment":30,"completionDate":"2036-05"},{"nctId":"NCT03054363","phase":"PHASE1,PHASE2","title":"Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-11-27","conditions":["Breast Cancer"],"enrollment":42,"completionDate":"2023-02-07"},{"nctId":"NCT06067776","phase":"PHASE1","title":"Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jonathan Riess","startDate":"2024-01-01","conditions":["Metastatic Lung Non-Small Cell Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":36,"completionDate":"2026-11-01"},{"nctId":"NCT02614794","phase":"PHASE2","title":"A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","isPivotal":true,"startDate":"2016-01-28","conditions":["HER2 Positive Breast Cancer"],"enrollment":612,"completionDate":"2022-08-11"},{"nctId":"NCT04896320","phase":"PHASE1,PHASE2","title":"Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.","status":"WITHDRAWN","sponsor":"Providence Health & Services","startDate":"2021-12-15","conditions":["Breast Cancer Stage IV"],"enrollment":0,"completionDate":"2023-06-19"},{"nctId":"NCT05190445","phase":"PHASE2","title":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pieris Pharmaceuticals, Inc.","startDate":"2021-11-01","conditions":["HER2-positive Gastric Cancer"],"enrollment":80,"completionDate":"2023-02-01"},{"nctId":"NCT05091528","phase":"PHASE1,PHASE2","title":"A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers","status":"TERMINATED","sponsor":"Silverback Therapeutics","startDate":"2022-02-08","conditions":["HER2-positive Breast Cancer","HER2-positive Gastric Cancer","HER2-positive Colorectal Cancer","HER2-expressing Non-small Cell Lung Cancer"],"enrollment":2,"completionDate":"2022-07-07"},{"nctId":"NCT05227131","phase":"PHASE2","title":"Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"MedSIR","startDate":"2022-05-15","conditions":["Metastatic Breast Cancer","Advanced Breast Cancer","HER2-positive Breast Cancer"],"enrollment":0,"completionDate":"2024-10"},{"nctId":"NCT04512261","phase":"PHASE1,PHASE2","title":"TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases","status":"WITHDRAWN","sponsor":"Reva Basho","startDate":"2022-06-01","conditions":["Breast Cancer","Brain Metastases","HER2-positive Breast Cancer","CNS Disease"],"enrollment":0,"completionDate":"2024-06-01"},{"nctId":"NCT04760431","phase":"PHASE2","title":"TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-10-01","conditions":["HER2-positive Breast Cancer","Brain Metastases"],"enrollment":120,"completionDate":"2025-09-30"},{"nctId":"NCT03846583","phase":"PHASE1","title":"Tucatinib + Abemaciclib + Herceptin for HER2+ MBC","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-06-28","conditions":["Breast Cancer"],"enrollment":0,"completionDate":"2020-09-22"},{"nctId":"NCT01983501","phase":"PHASE1","title":"A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2014-02-28","conditions":["HER2 Positive Breast Cancers"],"enrollment":57,"completionDate":"2020-09-03"},{"nctId":"NCT02025192","phase":"PHASE1","title":"A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2013-12-31","conditions":["HER2 Positive Metastatic Breast Cancers"],"enrollment":60,"completionDate":"2020-03-16"},{"nctId":"NCT03424473","phase":"","title":"Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Seagen Inc.","startDate":"","conditions":[],"enrollment":0,"completionDate":""},{"nctId":"NCT03723395","phase":"PHASE1","title":"A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2018-09-17","conditions":["Drug-drug Interaction"],"enrollment":116,"completionDate":"2018-12-28"},{"nctId":"NCT03914755","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2019-05-08","conditions":["Healthy"],"enrollment":36,"completionDate":"2019-08-04"},{"nctId":"NCT03722823","phase":"PHASE1","title":"A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2018-10-10","conditions":["Hepatic Impairment"],"enrollment":37,"completionDate":"2019-05-07"},{"nctId":"NCT03777761","phase":"PHASE1","title":"Effects of Tucatinib on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2018-12-06","conditions":["Healthy"],"enrollment":55,"completionDate":"2019-03-11"},{"nctId":"NCT03826602","phase":"PHASE1","title":"A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2019-02-12","conditions":["Drug-drug Interaction"],"enrollment":18,"completionDate":"2019-03-15"},{"nctId":"NCT03758339","phase":"PHASE1","title":"A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants","status":"COMPLETED","sponsor":"Cascadian Therapeutics Inc.","startDate":"2017-12-30","conditions":["Healthy"],"enrollment":8,"completionDate":"2018-01-30"}],"_emaApprovals":[{"date":"2021-02-11","status":"Authorised","company":"SEAGEN B.V"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT02614794"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"TUKYSA"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"333110","NDDF":"018332","UNII":"234248D0HH","VANDF":"4039346","INN_ID":"9997","RXNORM":"2361285","UMLSCUI":"C4519167","chemblId":"CHEMBL3989868","ChEMBL_ID":"CHEMBL3989868","KEGG_DRUG":"D11141","DRUGBANK_ID":"DB11652","PUBCHEM_CID":"51039094","SNOMEDCT_US":"871698009","IUPHAR_LIGAND_ID":"9922","MESH_SUPPLEMENTAL_RECORD_UI":"C000705452"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2020-","companyName":"Seattle Genetics","relationship":"Original Developer"},{"period":"present","companyName":"Seagen","relationship":"Current Owner"},{"period":"2021","companyName":"Seagen B.V","relationship":"EMA Licensee"}],"publicationCount":277,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:58:26.174994+00","atcClassification":{"source":"DrugCentral","atcCode":"L01EH03","allCodes":["L01EH03"]},"biosimilarFilings":[],"originalDeveloper":"Seattle Genetics","recentPublications":[{"date":"2026 Mar 19","pmid":"41899598","title":"Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy.","journal":"Cancers"},{"date":"2026 Mar 13","pmid":"41899536","title":"Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer.","journal":"Cancers"},{"date":"2026 Mar 20","pmid":"41899309","title":"Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.","journal":"Journal of clinical medicine"},{"date":"2026 Mar 18","pmid":"41851506","title":"Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2(+) breast cancer: TBCRC049 phase 2 study results.","journal":"Nature cancer"},{"date":"2026 Mar 13","pmid":"41824101","title":"Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.","journal":"Breast cancer research and treatment"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Seagen","companyId":"seagen","modality":"Small Molecule","firstApprovalDate":"2020","enrichmentLevel":4,"visitCount":7,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-04-17T00:00:00.000Z","mah":"SEAGEN","brand_name_local":null,"application_number":"NDA213411"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":35,"withResults":9},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:42:44.572021+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}